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 Introduction 1 
1 Introduction 
 
1.1 Food allergy 
The prevalence of food allergies has increased over the last decades.(1) Food allergies are adverse 
immune reactions to otherwise innocuous food proteins.(1) Epidemiologic studies involving controlled 
food challenges for the diagnosis of food allergies indicated that 1 % to 10.8 % of the population have 
immune-mediated non-toxic food hypersensitivity.(1) Food allergies in small children are caused by 
various types of food including cow’s milk, hen’s egg, peanuts, tree nuts and shellfish.(1, 2) The major 
foods causing allergies in adults except pollen-related food allergy to fruits and vegetables are 
shellfish, tree nuts, cereals and peanuts.(3-5) In adulthood, allergy to cow’s milk or hen’s egg is of low 
prevalence.(3, 4) Food allergic patients suffer from symptoms affecting cutaneous, respiratory and 
gastrointestinal tissues and in the worst case systemic anaphylactic shocks occur, which can be 
life-threatening.(6) Unfortunately, many types of food allergy are persistent for life and thus, the 
quality of life of the allergic patients is dramatically reduced.(2, 6)  
Until today, the only proven management for food allergies is the elimination of the allergenic foods 
from the diet.(2, 6) However, this is difficult in the case of ubiquitous foods such as milk and egg, 
which are ingredients of many compound foods and processed foods, e.g. bakery products.(2, 6) 
Non-precise labelling of compound foods or cross-contamination of foods in the production process by 
usage of the same equipment for allergen-free and allergen-containing foods are the main causes of 
inadvertent food intake.(2, 6) For an inadvertent intake of the allergenic foods a symptomatic 
treatment, antihistamines or other medications, is available.(2, 6) As a potential curative treatment, 
allergen-specific immunotherapy (SIT) has gathered great interest.(6, 7) SIT aims to induce 
desensitization or clinical tolerance, i.e. immunologically non-response condition, by continuous 
administration of allergen(s).(6, 7) However, recent clinical studies have shown limited efficacy and 
safety of SIT for persistent food allergies.(8, 9) To establish a safe and effective treatment, it is 
crucially important to elucidate the pathomechanisms of food allergies. 
 
 
1.1.1 Basic pathomechanism of allergy 
Most types of allergy including food allergy belong to the class of type I hypersensitivity reactions, 
whose mechanism is schematically depicted in figure 1.(7, 10) Clinical symptoms in type I hypersen-
sitivity reactions are mediated by allergen-specific immunoglobulin E (IgE).(7, 10) 
Contact of the immune system with an allergen may break innate tolerance and initiate the 
sensitization phase.(2, 10) The respective allergen is taken up by an antigen-presenting cell (APC), like 
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a dendritic cell (DC) or a macrophage.(10) Inside the cell, the allergen is processed into small 
antigenic peptides, which are then loaded onto major histocompatibility complex (MHC) class II 
molecules and are presented on the cell surface.(10) Binding of a specific T-cell receptor (TCR) on a 
naive CD4
+
 T-cell to the MHC class II peptide complex leads to T-cell activation and 
differentiation.(11) T-cell differentiation depends on the cytokine milieu (see chapter 1.6).(11) 
Allergy is mediated by T helper 2 (TH2) cells, a subset of CD4
+
 effector T-cells.(7, 10) TH2 cells 
produce the cytokines interleukin-4 (IL-4), IL-5, and IL-13. IL-4 and IL-5 induce maturation of mast 
cells and eosinophils, respectively.(10, 11) Moreover, IL-4 and IL-13 induce class switching and the 
production of allergen-specific IgE antibodies by B-cells.(7) The secreted IgE antibodies are captured 
by the high affinity IgE receptor, FcεRI, on the cell surface of mast cells or basophils.(7) The allergic 
response is suppressed by IL-10 or transforming growth factor-β (TGF-β) produced by TH1 cells or 
regulatory T-cells (TRegs), other CD4
+
 effector T-cell subsets.(7, 10) 
Subsequent exposure to the allergen after sensitization provokes the elicitation phase.(10) The allergen 
cross-links the captured IgE antibodies on the cell surface, which subsequently induces mast cell and 
basophil degranulation.(7, 10) This step to induce degranulation is called the early-phase reaction.(7, 
10) Mast cells and basophils then release the anaphylactic mediator histamine and other 
physiologically active substances inducing the immediate allergic symptoms.(7, 10)  
The late phase allergic reaction is characterized by a more sustained mainly cell-mediated 
inflammation, in contrast to the above mentioned IgE-mediated acute symptoms.(10) Activated mast 
cells release prostaglandins, cytokines (e.g. IL-5 and IL-13) and chemokines (e.g. CC chemokine 
ligand 3 (CCL3), CCL5 and CCL11) which recruit other leukocytes, like TH2-cells and eosinophils, to 
local tissues.(10) Finally, cytokines and tissue-damaging proteases secreted by these cells are 
responsible for chronic allergic inflammation.(10) 
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Figure 1: Overview over the basic pathomechanism of allergy. Allergen contact may trigger (A) the sensitization phase 
and immediate allergic symptoms are induced by (B) the elicitation phase upon repeated allergen exposure. 
 
 
 
1.1.2 Egg allergy and its model allergen ovalbumin 
Egg allergy is one of the most prevalent food hypersensitivities in infants and small children.(12-14) It 
was thought that the majority of children with an egg allergy become tolerant to hen’s egg by school 
age.(2) However, a recent study suggested that egg allergy persists into adolescence.(15) The most 
clinically relevant major egg white allergen is ovomucoid, whereas ovalbumin (OVA) is the most 
abundant one with about 54 % of the whole egg white protein.(16) Although its allergenicity is weaker 
than that of ovomucoid, OVA is used as a reference protein in biochemistry and as a model allergen in 
immunology and allergology due to its high amount in egg white and its availability as single purified 
protein in high amounts.(16, 17) The allergen used in this thesis is this major chicken egg white 
allergen OVA. 
OVA is built up of 386 amino acids (aa) resulting in a molecular weight of about 45 kDa. The protein 
fold is made up of nine α-helices and three β-sheets containing one disulphide bond, two 
phosphorylated serine residues and a mannose-rich glycosylation on Asn293.(16, 18, 19) This 
structural motif belongs to the serine protease inhibitor superfamily.(17) The single glycosylation on 
Asn293 consists of branched chains of neutral glycans linked to OVA by N-acetylglucosamine 
(GlcNAc).(19, 20) These glycans are mainly of the high-mannose (consisting of five to six mannose 
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(Man) and two GlcNAc residues) type or the hybrid type (varying composition also with high 
abundance of Man in relation to GlcNAc and galactose).(19, 20)  
The biochemical, the immunological and the allergenic properties of OVA have been extensively 
studied. The T-cell epitopes of OVA in human and several mice strains share a common 
immunodominant epitope in the region of aa 323 – 339, suggesting that mice reacting to this 
OVA323-329 peptide could be used as a model of egg allergy.(16) Other immunodominant peptides 
recognized by human TCRs are aa 1 – 33, aa 105 – 122, aa 198 – 213 and aa 261 – 277.(16) 
Additionally, the immunodominant sequences bound by IgE from allergic patients are located in the 
segments of aa 39 – 49, aa 95 -102, aa 191 – 200, aa 243 – 248 and of aa 251 - 260 and are only 
marginally overlapping with the peptides recognized by TCRs.(21) There seems to be no similarity in 
the peptides bound by human and murine IgE antibodies, but the sequences in both groups consist 
mainly of hydrophobic and charged amino acids.(21, 22) In BALB/c mice the immunodominant 
peptides recognized by IgE from sensitized mice are aa 53 – 60, aa 77 - 84, aa 103 – 108, aa 127 - 136, 
aa 275 – 280, aa 301 – 306, aa 323 – 329 and aa 375 – 384.(22) Another key feature of OVA is its 
relative stability against intestinal digestion and thermal processing.(16, 23) For example, Astwood et 
al. showed that OVA stayed intact after 60 min digestion in simulated gastric fluid.(24) All these facts 
together with the many established murine models of allergic diseases using OVA made this allergen 
an excellent candidate for this study. 
 
 
1.2 Impact of thermal processing on the allergenicity of foods 
The majority of foods is processed before being consumed and this can influence the immunogenic 
and allergenic properties of food allergens.(23, 25) The most common food processing techniques 
cooking, roasting, boiling and frying may cause protein unfolding, aggregation and/or chemical 
modification of the respective proteins.(25, 26) There are many factors influencing the extent of 
protein changes, like the temperature, the processing method, the food matrix and the duration of the 
treatment, thus, making a prediction of the outcome regarding the protein structure and its allergenicity  
difficult.(25, 26) 
A reduction in allergenicity after cooking has been observed for many types of fruits or vegetables, 
e.g. Bet v 1 homologue allergens, the major cherry allergen Pru av 1, the major carrot allergen Dau c 1 
and the allergen Api g 1 from celery.(23, 27-29). Thermal processing of the egg white allergen OVA 
has also been studied and a reduction in immunogenicity and allergenicity was observed.(30-32) In all 
studies heat-induced structural changes of OVA contributed to a higher susceptibility to gastric 
digestion and reduced IgE-binding of sera from allergic patients.(30-32) The opposite effect, i.e. 
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tolerance of the raw food and induction of allergic symptoms by consumption of the respective food in 
its cooked state has been observed for shrimp, shellfish and pecan nuts.(33-35) For the highly 
allergenic peanuts a comparison of the allergenicity of raw and roasted peanuts is difficult, because 
they are primarily consumed after roasting.(36, 37) Nevertheless, there is evidence that roasting may 
increase the allergenic properties of peanut allergens by reducing the susceptibility of the proteins 
towards degradation and gastric digestion.(36, 37) The enhanced allergenicity of all mentioned 
allergenic foods including peanuts was not only caused by structural changes of the proteins, like 
denaturation of conformational epitopes and exposure of usually buried linear ones, but also by 
chemical modification of the allergens.(25, 26) 
During thermal processing of foods, proteins chemically react with many components such as 
carbohydrates, lipids and the food matrix.(25, 26) The main chemical reaction between proteins and 
carbohydrates is the Maillard reaction.(25, 26) 
 
 
1.3 The Maillard reaction 
The Maillard reaction was identified by Louis Camille Maillard in 1912.(38) It is a non-enzymatic 
glycation reaction between the carbonyl group of a reducing sugar and compounds with free amino 
groups, like amino acids or proteins, occurring during thermal processing or long-term storage of foods 
as well as in vivo during the process of aging.(38, 39) The condensation of sugar and protein in the 
early phase Maillard reaction results in the formation of so-called Amadori products, e.g. 
N
ε
-fructosyllysine, N
ε
-lactulosyllysine or protein-bound polysaccharides.(39) In the advanced phase 
Maillard reaction these Amadori products become degraded to highly reactive 1,2-dicarbonyl 
substances, which subsequently react in a complex cascade finally forming stable Maillard reaction 
products.(39) The stable products at the final stage of the Maillard reaction are collectively called 
Advanced Glycation Endproducts (AGEs).(39) A scheme of the overall Maillard reaction with 
representative AGE-structures as final products is shown in figure 2. The shown reaction products are 
only a selection of a pool of several hundreds of different compounds, which are known to be formed 
by the complex cascade of the Maillard reaction.(39, 40) 
Until today a vast variety of different AGE-structures linked to either lysine or arginine residues in 
proteins have been identified.(41) The first AGEs identified in foods were the melanoidins, a collective 
term for all brown-coloured AGEs, since the Maillard reaction is also called a non-enzymatic 
browning reaction.(39, 41) Besides of the brown colour, the melanoidins and many other AGEs also 
contribute to the flavour and the aroma of processed foods.(42, 43) Some representative AGEs found 
in foods are N
ε
-carboxymethyllysine (CML), pentosidine, pyrraline as well as hydroimidazolones.(39, 
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43) Some of the presented AGE-structures, like CML, are also formed by the in vivo Maillard reaction 
during aging.(44) It has been suggested that products of the in vivo Maillard reaction trigger 
inflammation and thus, contribute to the pathology of human diseases, e.g. diabetes, rheumatoid 
arthritis or Alzheimer’s disease.(44) 
 
 
Figure 2: Simplified mechanism of the Maillard reaction resulting in the formation of AGE-structures. 
Representative AGEs found in processed foods are N
ε
-fructoselysine (1), CML (2), pentosidine (3), pyrraline (4) and 
methylglyoxal-induced hydroimidazolones (5). 
 
 
1.3.1 AGE-binding receptors 
The contribution of AGEs in the pathology of many diseases has led to the identification of several 
receptors binding to AGEs. Important receptors binding to AGEs are schematically shown in figure 3. 
First, the receptor for AGEs (RAGE) was identified in 1992 by Schmidt et al.(45) together with 
Neeper et al.(46) as the one mediating the binding of AGEs to endothelial cells in the pathogenesis of 
diabetic angiopathy.(45, 46) Several studies have shown a possible involvement of RAGE in 
Alzheimer’s disease and diabetic complications by inducing an inflammatory signal.(44) 
Using the macrophage-like cell line RAW264.7, Vlassara et al.(47) reported the binding of 
AGE-modified proteins to galectin-3, which usually binds to galactose-containing carbohydrates.(47) 
Several members of the macrophage scavenger receptor family, another group of carbohydrate binding 
receptors, were also identified to bind to AGEs.(48, 49) Araki et al. showed that the endocytosis of 
AGE-modified BSA is mediated by macrophage scavenger receptors class A type I and type II 
(SR-AI/II).(50) Ohgami et al. found that the class B scavenger receptors SR-BI and CD36 are 
AGE-binding receptors.(51, 52) 
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Importantly, RAGE, galectin-3, SR-AI/II, SR-BI and CD36 are expressed on the surface of APCs and 
thus, binding of food allergens linked to AGE-structures to these receptors could have an influence on 
cell function. 
 
 
Figure 3: AGE-binding receptors (inspired by Horiuchi et al.(49)). 
 
 
1.3.1.1 Scavenger receptors 
The members of the scavenger receptor family are endocytic and phagocytic receptors expressed on 
the surface of DCs and macrophages.(53, 54) Many scavenger receptor ligands are polyanionic 
molecules.(53, 54) Identified ligands of scavenger receptors are AGEs, oxidized and acetylated low 
density lipoproteins (oxLDL respectively acLDL), lipopolysaccharide (LPS) as well as gram-positive 
bacteria.(48, 53, 54) The scavenger receptors are divided into eight classes (class A to H) based on 
their structure and only class A and class B scavenger receptors, which are schematically depicted in 
figure 4, have been reported to bind to AGEs.(48, 54) 
 
 
Figure 4: Domain structure of class A and class B scavenger receptors (inspired by Plüddemann et al.(48)). 
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Class A scavenger receptors (SR-A) are transmembrane glycoproteins and are composed of a 
cytoplasmic tail, a transmembrane region, an extracellular spacer, an -helical coiled-coil domain, a 
collagenous domain and a C-terminal scavenger receptor cysteine-rich domain.(48) Antigen 
recognition by and binding to the collagenous domain of the functional equivalent isoforms SR-A 
type I and type II (summarized as SR-AI/II) induces endocytosis, which is mediated by the 
cytoplasmic tail of the receptor.(48, 55) Antigen endocytosis leads to antigen-presentation for the 
induction of an adaptive TH response as well as cytokine secretion by the APC, originally determined 
for the clearance of bacterial infections.(48, 53) 
 
The class B scavenger receptors CD36 and SR-BI are also transmembrane glycoproteins and consist of 
two short intracellular tails and a highly glycosylated extracellular loop.(48) The first binding of AGEs 
to CD36 and SR-BI in vitro was shown by Ohgami et al.(51, 52) Furthermore, the natural ligand 
oxLDL and AGEs are recognized by the same region in the extracellular domain.(52) Antigen 
internalization for antigen-presentation is then mediated by the C-terminal intracellular domain.(48) 
The natural function of SR-BI is in the metabolism of high density lipoprotein and control of 
cholesterol efflux.(49) AGEs served in vitro as inhibitor of SR-BI mediated cholesterol efflux, hence, a 
contribution of AGEs in vivo on SR-BI function can not be excluded although it was not yet 
demonstrated.(49) 
 
 
1.3.1.2 Galectin-3 
The natural ligands of the galectin receptor family including galectin-3 are β-galactoside carbohydrates 
and their interaction is important in many different regulatory processes as well as in allergy by 
activation of mast cells.(56, 57) 
Galectin-3 is built up of the ligand-binding C-terminal carbohydrate-recognition domain and a highly 
conserved N-terminal domain with tandem repeats and has a molecular weight of about 35 kDa. The 
expression of the receptor is not limited to a specific cell type or tissue as galectin-3 is expressed by 
macrophages, DCs, monocytes, neutrophils as well as epithelial cells of nearly all organs.(56) Another 
unique feature of galectin-3 is that the receptor can be found in the cytoplasm, in the cell nucleus, on 
the cell surface or extracellularly as a soluble form.(47) 
As a cell surface receptor galectin-3 is involved in cell adhesion, cell signalling as well as immune 
reactions by binding bacterial glycans and induction of its pro-inflammatory activity.(56) It has been 
suggested that the interaction of galectin-3 with AGEs is involved in the pathogenesis of 
atherosclerosis.(58) 
 Introduction 9 
1.3.1.3 The mannose receptor 
Another receptor family recognizing carbohydrate structures are C-type lectin receptors (CTLs).(59, 
60) CTLs have an important role in innate immunity in the endocytosis of pathogens by APCs.(59, 60) 
Many glycosylated allergens are recognized by CTLs, e.g. the egg white allergen OVA, the peanut 
allergen Ara h 1 as well as the house dust mite allergens Der p 1 and Der p 2.(59, 61) 
 
The CTL mainly mediating the uptake of allergens is the macrophage mannose receptor (MR; 
CD206).(60, 61) The MR is primarily expressed on the surface of DCs and macrophages.(60, 61) The 
MR structurally is composed of an N-terminal cysteine-rich domain, a domain containing fibronectin 
type II repeats, eight C-type lectin-like domains, a transmembrane domain and a short cytoplasmic 
tail.(54, 62) Pathogens are bound by the C-type lectin-like domains, a unique feature of CTLs, and the 
domains of the MR have a strong affinity for glycans containing high levels of mannose and to a lesser 
extent glucose or fucose.(60, 61) The bound antigens are then transported by the cytoplasmic tail into 
the cytoplasm, where they are processed followed by presentation by MHC molecules on the cell 
surface.(54, 62) The detailed mechanisms of antigen routing after MR uptake are yet not fully 
understood. It has been suggested that the nature of the pathogen determines the type of immune 
reaction, either TH1-type response, TH2-type response or cross-presentation to CD8
+
 T-cells.(63) 
Cross-presentation means that antigens, which are usually presented to CD4
+
 T-cells by MHC class II 
molecules, like exogenous antigens, are transported to the MHC class I loading pathway and thus, are 
presented to CD8
+
 T-cells.(64) 
 
 
1.3.2 AGEs and food allergy 
In the literature, there is a controversial discussion about the impact of the Maillard reaction on the 
allergenic properties of food allergens.(41) 
Several studies have investigated the influence of the Maillard reaction on peanuts, a highly allergenic 
food causing severe anaphylactic shocks. Roasting seems to enhance peanut allergenicity, because a 
stronger binding of IgE from peanut allergic patients to extracts from roasted peanuts compared to raw 
peanuts has been observed.(37, 65) This binding could be inhibited by AGE-specific antibodies and 
thus, could be linked to modifications by the Maillard reaction in roasted peanuts.(65) On the other 
hand, other studies suggested that the Maillard reaction attenuates the allergenic potency of peanut, 
because of reduced IgE-reactivity and mediator release capacity after glycation.(66, 67) A reduced 
allergenicity after modification with Maillard reaction products has also been observed for the major 
cherry allergen, for β–lactoglobulin in milk, as well as for tropomyosin in fish.(27, 68-70)  
 Introduction 10 
There is evidence that the Maillard reaction is not only influencing IgE-reactivity and mediator release 
capacity, i.e. characteristics for the elicitation of food allergy, but can also play a role earlier in the 
pathology, e.g. in the interaction of the allergen with an APC or in T-cell activation. In the study by 
Ilchmann et al. glycated OVA (AGE-OVA) activated allergen-specific T-cells to a stronger extent than 
the native allergen.(71) This enhanced CD4
+
 T-cell activation was mediated by an enhanced uptake of 
AGE-OVA by DCs.(71) It was suggested that SR-AI/II could mediate the uptake of AGE-OVA by 
DCs.(71) These results showed that the Maillard reaction enhances the T-cell immunogenicity of 
OVA, which in turn might enhance the allergenic potency of the food allergen.(71) 
All mentioned studies have in common that crude glycated foods or the respective food allergens were 
analyzed. The profile of the formed glycation structures is highly dependent on the chosen conditions, 
such as the sugar component, the temperature, the duration, the pH and the food matrix.(26, 41) Hence, 
the glycation structures contributing to this vast spectrum of results are not known. It is of great 
importance to investigate the influence of representative glycation structures on the immunological and 
allergenic properties of food allergens.  
 
 
1.4 Dendritic cells 
DCs are the unique and crucial bridge between innate and adaptive immunity.(72, 73) The main 
function of DCs is recognition, uptake and presentation of antigens followed by subsequent induction 
of an antigen-specific adaptive immune response.(72) The encounter of a DC with an antigen results in 
cell activation and maturation.(74) 
The primarily occurring mechanism of antigen uptake is receptor-mediated endocytosis by 
pattern-recognition receptors (PRRs), like macrophage scavenger receptors, CTLs or toll-like receptors 
(TLRs), in addition to macropinocytosis or phagocytosis of the antigen.(75) The recognition of and 
binding of an antigen by a surface-exposed receptor via innate immune mechanisms triggers the 
budding of the cell membrane and the protein is transported to the cytosol in a small vesicle called 
endosome for intracellular processing to generate antigenic peptides.(10) 
Some PRRs such as TLRs are involved not only in antigen uptake, but also in activation and 
maturation of DCs.(61, 75) During this transformation of the DC into a functional APC, the expression 
of surface PRRs is downregulated and co-stimulatory molecules, e.g. CD40, CD80 (B7.1) and CD86 
(B7.2) become upregulated.(75) Subsequently, the cell morphology changes and antigenic 
peptide-loaded MHC molecules are transported to the cell surface.(75) The maturation process is also 
regulated by secretion of cytokines, e.g. IL-1, IL-6, IL-10, IL-12 and tumour necrosis factor-α 
(TNF-α).(74, 75) 
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The nature of the antigen determines the route of antigen processing and presentation pathway in DCs, 
i.e. endogenous antigens, e.g. viral or tumour antigens, are delivered to the MHC class I presentation 
pathway, whereas extracellular antigens, e.g. allergens or particulates, will be delivered to the 
MHC class II presentation pathway.(75) There is also the possibility of cross-presentation, which 
means that exogenous antigens are delivered to the MHC class I presentation pathway, but the exact 
mechanisms of cross-presentation are not yet completely understood.(75) For presentation of the 
antigenic peptide-MHC class I or class II complex to naive CD8
+
 or CD4
+
 T-cells, respectively, the 
mature DCs migrate to the draining lymphoid organs. There, an adaptive immune response is induced 
by binding of an antigen-specific TCR to the MHC complex in combination with signalling of the 
co-stimulatory molecules.(74, 75)  
 
 
1.5 Macrophages 
Macrophages are monocyte-derived cells with important functions in innate as well as in adaptive 
immunity.(76) Although there is an exceptionally high diversity of resident macrophages due to 
intrinsic differentiation pathways in the tissues, two main classes of activated cells mediating the 
majority of immune responses, i.e. M1 and M2 macrophages, have been described.(76, 77) In the 
literature, M1 macrophages are also referred to as classically activated macrophages with a mainly 
pro-inflammatory phenotype, whereas M2 macrophages, or alternatively activated macrophages, 
basically are involved in tissue repair and homeostasis as well as TH2-type immune responses.(76, 78) 
Like in DCs, activation of resting macrophages is induced by a so-called danger signal, like the 
recognition of a pathogen or the presence of a specific cytokine.(77) PRRs, like some TLRs, CTLs and 
scavenger receptors, are expressed on the surface of macrophages and mediate endocytosis of 
exogenous ligands.(79) 
The uptake of microbial related structures, like LPS, or the presence of interferon-γ (IFN-γ) leads to 
differentiation into M1 macrophages. M1 macrophages participate as inducer or effector cells in 
TH1-type immune responses and thus, surface expression of co-stimulatory molecules together with 
MHC class II molecules is upregulated.(76, 79) The high level of MHC class II expression is 
accompanied by strong antigen-presentation to CD4
+
 T-cells.(78) For an effective clearance of viral 
and microbial infections, M1 macrophages produce the pro-inflammatory cytokines IL-1β, IL-6, IL-12 
and TNF-α.(76, 77) The microbicidal activity of these cytokines is assisted by the production of 
reactive nitrogen and oxygen species.(78) 
The pro-inflammatory activities of M1 macrophages can be suppressed by M2 macrophages, which 
become activated by the cytokines IL-4 or IL-13.(76, 80) Like M1 cells, also M2 macrophages have a 
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high pre-disposition to function as APCs and activation leads to high expression of MHC class II 
molecules.(79) In M2 cells, contributing to the function as APC is the enhanced density of scavenger, 
mannose and galactose receptors on the cell surface for efficient parasite recognition.(78, 79) Besides 
assistance in parasitic and allergic TH2 responses, M2 cells are also important for the suppression of 
inflammation and for tissue repair. As part of these functions M2 cells produce the anti-inflammatory 
cytokines IL-10 and TGF-.(76, 78) 
Because of the high plasticity of macrophages, the role of macrophages in food allergy and many other 
AGE-associated diseases, e.g. diabetic complications and Alzheimer’s disease, is heavily 
discussed.(44, 81, 82) However, the association of M1 and M2 cells with AGEs has not yet been 
investigated. 
 
 
1.6 T-cells 
T-cells play a crucial role in adaptive immunity.(10, 11) The cells are divided upon their bearing 
co-receptors into CD4
+
 and CD8
+
 T-cells.(10, 11) The main function of CD4
+
 T-cells, which are also 
called TH cells, is the activation of other leukocytes, whereas that of CD8
+
 T-cells, which are also 
called cytotoxic T-lymphocytes, is clearance of microbial infections as well as killing of virus-infected 
and tumour cells.(10) Activated CD4
+
 T-cells are the prerequisite for the activation of B-cells and their 
subsequent differentiation into immunoglobulin-secreting plasma cells.(7, 10) 
Two signals are required for the activation of both T-cell classes if they are in their naive state.(10, 74) 
First, a peptide-MHC complex presented by an APC is bound by a specific TCR.(10, 74) Thereby 
peptides presented on MHC class II molecules are recognized by CD4
+
 T-cells, whereas peptides 
presented on MHC class I molecules are recognized by CD8
+
 T-cells.(10) The second signal is 
provided by co-stimulatory molecules, like CD80 or CD86 expressed by the APC and CD28 on the 
surface of the T-cell.(74) These two signals are sufficient for triggering T-cell clonal expansion, i.e. 
proliferation, and IL-2 production by the T-cell, which provides the last signal.(10, 74) High levels of 
IL-2 promote T-cell clonal expansion.(11) 
The determining factor for T-cell differentiation is the cytokine milieu.(10) IFN-γ and IL-12 lead to the 
development of TH1-cells, which assist infected macrophages in pathogen killing or provide help for 
the clearance of extracellular pathogens by activating antibody production by B-cells.(10, 11) 
Differentiation into TH2-cells is induced by IL-4.(7) TH17-cells, another subset, which has been 
recently identified, are responsible for autoimmunity and are induced by IL-6 and TGF-β.(83) 
Disruption of the natural balance among the T-cell subsets leads to disease.(11) Allergic inflammation 
is caused by excessive numbers of TH2-cells.(7, 11) This response can be suppressed by high amounts 
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of IFN-γ produced by TH1-cells.(7, 11) Recent studies have suggested that TH17 cells could play a role 
in allergic inflammation, e.g. by recruitment of neutrophils, another type of inflammatory leukocytes, 
and by induction of the release of inflammatory mediators by resident tissue cells, like epithelial 
cells.(83) Another mechanism controlling the immune response is the induction of TRegs, which are 
able to suppress TH responses by secretion of the suppressive cytokines IL-10 and TGF-β.(7) 
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2 Objective 
 
The aim of this thesis is to investigate molecular mechanisms of the influence of the Maillard reaction, 
which occurs during thermal processing of foods, on the immunogenic and allergenic properties of 
food allergens. The previous study by Ilchmann et al. showed that CD4
+
 T-cell immunogenicity of 
OVA, a model food allergen, is enhanced, when it is glycated by the Maillard reaction during thermal 
incubation with glucose.(71) This Maillard reaction product of OVA with glucose contained various 
glycation structures.(71) Notably, several studies showed that receptors binding to crude products of 
the Maillard reaction, e.g. SR-AI/II and CD36, could bind only to distinct glycation structures.(84, 85) 
Based on this background, the working hypothesis for this thesis was that distinct glycation 
structure(s) contribute to the enhanced CD4
+
 T-cell immunogenicity of crude glycated OVA 
(AGE-OVA). To verify the hypothesis, OVA was selectively modified with the glycation structures 
N
ε
-carboxyethyllysine (CEL), CML, methylglyoxal-induced hydroimidazolones (MG-H1) or pyrraline, 
which are representative glycation structures found in processed foods. The following experimental 
aims were set up: 
(1) To investigate the immunogenic properties of these OVA samples modified with distinct 
glycation structures using cultured murine DCs and T-cells. 
(2) To investigate the allergenic properties of the glycated OVAs using a murine model of food 
allergy. 
(3) To investigate the immunogenic properties of the glycated OVAs using cultured human DCs 
and macrophages. 
 
First, a detailed characterization of the modified OVAs with chromatographic methods or by means of 
enzyme-linked immunosorbent assay (ELISA) was performed. The immunogenic properties of the 
modified OVA samples in comparison to AGE-OVA or native OVA were then investigated using in 
vitro cell culture assays. The ability of the allergens to activate transgenic allergen-specific 
CD4
+
 T-cells and CD8
+
 T-cells, which is crucial for provoking immune responses, was assessed using 
a co-culture system of these T-cells with bone marrow-derived DCs. The capacity of the modified 
OVAs to induce DC maturation as well as uptake of fluorescent-labelled OVA samples by DCs was 
assessed by flow cytometric analyses. Afterwards, the molecular uptake mechanism was investigated 
by inhibiting putative receptors playing a central role in endocytosis of OVA or AGE-modified 
proteins, or using DCs deficient for the putative receptor. Immunocytochemistry was performed to 
identify the intracellular compartment containing the glycated allergen by confocal microscopy, which 
could elucidate a pathway of receptor-mediated antigen delivery for antigen presentation. 
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In the second part of this thesis, the allergenic potency of AGE-OVA and selectively modified OVAs 
with enhanced T-cell immunogenicity was investigated using an in vivo mouse model of intestinal 
food allergy. BALB/c mice were sensitized with either form of OVA in combination with a 
TH2-directing adjuvant and afterwards orally challenged with the allergen. As a measure of 
immunogenicity, T-cell responses of CD4
+
 T-cells isolated from the mesenteric lymph nodes, the gut 
draining lymphoid organ, were assessed in vitro. In addition, the humoral immune response was 
elucidated by determining the levels of IgE, IgG1 and IgG2a antibodies in the sera of the mice. 
Allergenic potency of the modified OVAs was investigated by monitoring clinical symptoms, like loss 
of bodyweight, drop in body temperature and diarrhoea, during the challenge. 
Finally, a system of human cell culture for studying the influence of the Maillard reaction on the 
immunogenic properties of OVA should be established, because tissue samples of egg allergic patients 
are very limited as most patients are small children. For this purpose, assays for investigating antigen 
uptake or DC maturation were transferred to cell culture of peripheral blood mononuclear cell 
(PBMC)-derived human DCs or macrophages. 
All parts of this thesis will contribute to a better understanding of the molecular mechanisms of food 
allergy. 
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3 Materials and Methods 
 
3.1 Materials 
 
3.1.1 Commonly used equipment 
 
Table 1: Commonly used devices and equipment in this thesis. 
equipment model company 
circular dichroism- 
(CD-) spectrometer 
J-810S JASCO (Groß-Umstadt) 
centrifuges centrifuge 5417C/R 
multifuge 1S-R 
Heraeus Varifuge 3.0R 
Eppendorf (Hamburg) 
Heraeus (Langenselbold) 
Heraeus (Langenselbold) 
ELISA reader Spectra Max 340 PC Molecular Devices (München) 
flow cytometers BD™ LSR II 
BD™ LSR II SORP 
Becton Dickinson (Heidelberg) 
Becton Dickinson (Heidelberg) 
incubator for cells BBD6220 CO2 incubator 
Labotect C-200 
Thermo Scientific (Nidderau) 
Labotect (Göttingen) 
laminar flow SterilGARD SG-400 The Baker Company (Sanford, ME, USA) 
magnetic stirrer IKAMAG® RCT basic IKA (Staufen) 
orbital shaker KS 130 control IKA (Staufen) 
power supply PowerPac™ 300 Bio-Rad Laboratories (München) 
scales Explorer Pro 
EK-300i 
Ohaus (Pin Brook, NJ, USA) 
AND (Abingdon, UK) 
seesaw shaker DUOMAX 1030 Heidolph Instruments (Schwalbach) 
thermo mixer Thermomixer Compact Eppendorf (Hamburg) 
vortex Vortex Genie 2 Scientific Industries (New York, USA) 
water bath Grant GD 100 Grant Instruments Ltd. (Cambridge, UK) 
 
Special equipment which was used for a single method is listed in the relevant method. 
 
 
3.1.2 Chemicals 
All chemicals were provided from Carl Roth (Karlsruhe), Sigma-Aldrich (Steinheim) or Merck 
(Darmstadt) if not stated otherwise. 
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3.1.3 Buffers 
All buffers were prepared using deionized water unless stated otherwise and were either autoclaved or 
sterile filtered. 
 
Table 2: General buffers used. 
buffer composition pH 
CD-buffer A 100 mmol/l KH2PO4 4.5 
CD-buffer B 100 mmol/l Na2HPO4 9.0 
EDTA/trypsin phosphate buffered saline (PBS) (see below) 
+ 0.1 % (w/v) ethylenediaminetetraacetic 
acid (EDTA) 
+ 0.25 % (w/v) trypsin 
 
ELISA blocking buffer PBS 
+ 2 % (w/v) bovine serum albumin (BSA) 
 
ELISA coating buffer 16 mmol/l Na2CO3 
34 mmol/l NaHCO3 
9.6 
ELISA washing buffer PBS 
+ 0.05 % (v/v) Tween 20 
7.1 
ELISA assay buffer PBS 
+ 1 % (w/v) BSA 
+ 0.05 % (v/v) Tween 20 
 
FACS-buffer PBS 
+ 1 % (w/v) BSA 
+ 20 mmol/l EDTA 
+ 0.03 % (w/v) NaN3 
 
HEPES 1 mol/l 2-[4-(2-hydroxyethyl)- 
piperazin-1-yl]ethane sulphonic acid 
7.9 
adjusted with NaOH 
ICC-assay buffer PBS 
+ 1 % (v/v) normal mouse serum 
+ 0.1 % (v/v) Triton® X-100 
 
MACS-buffer PBS 
+ 2 mmol/l EDTA 
+ 5 % (w/v) BSA 
7.2 
adjusted with HCl 
penicillin/ streptomycin/  
L-glutamine 
3.14 g/l penicillin G potassium salt 
5 g/l streptomycin sulphate 
15 g/l L-glutamine 
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buffer composition pH 
permeabilization-buffer PBS 
+ 5 % (w/v) skim milk powder 
+ 1 % (v/v) normal mouse serum 
+ 0.1 % (v/v) Triton® X-100 
+ 1 µg/ml normal mouse IgG 
 
phosphate buffer A 200 mmol/l NaH2PO4  
phosphate buffer B 200 mmol/l Na2HPO4  
phosphate-buffered saline 
(PBS) 
137 mmol/l NaCl 
2.7 mmol/l KCl 
1.45 mmol/l KH2PO4 
8.1 mmol/l Na2HPO4 
7.1 
adjusted with HCl 
SDS loading buffer 4x 0.25 mol/l tris(hydroxymethyl)amino- 
methane (TRIS) 
4.2 % (w/v) sodium dodecyl sulphate (SDS) 
20 % (v/v) glycerin 
2 % (w/v) bromophenolblue 
optional: + 10 % (v/v) 2-mercaptoethanol 
 
SDS running buffer 10x 250 mmol/l TRIS 
1.92 mol/l glycine 
10 % (w/v) SDS 
 
separation gel buffer 1.5 mol/l TRIS 
0.4 % (w/v) SDS 
8.8 
adjusted with HCl 
stacking gel buffer 0.5 mol/l TRIS 
0.4 % (w/v) SDS 
6.8 
adjusted with HCl 
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3.1.4 Cell culture media and reagents 
 
Table 3: Media composition and other reagents used for cell culture application in this thesis. 
medium composition application 
DC medium RPMI 1640 (Gibco®; Invitrogen, Darmstadt) 
+ 10 % (v/v) foetal calf serum (FCS) (Lot: 1088G) 
(Biochrom, Berlin) 
+ 10 mmol/l HEPES 
+ 1 mmol/l sodium pyruvate  
(Sigma-Aldrich, Steinheim) 
+ 1 % (v/v) penicillin/ streptomycin/ L-glutamine 
+ 0.1 mmol/l 2-mercaptoethanol  
(Sigma-Aldrich, Steinheim) 
murine BMDCs 
Ficoll Biocoll density 1.077 g/ml  
(Biochrom, Berlin) 
iDCs, mDCs 
human DC medium CellGro® GMP serum-free DC-medium  
(CellGenix, Freiburg) 
iDCs, mDCs 
LSM 1077 Lymphocyte Separation Medium  
(PAA Laboratories GmbH, Cölbe) 
human 
macrophages 
macrophage medium RPMI 
+ 10 % (v/v) FCS 
+ 1 % (v/v) penicillin/streptomycin/L-glutamine 
+ 10 mmol/l HEPES 
+ 0.05 mmol/l 2-mercaptoethanol 
human 
macrophages 
macrophage wash 
medium 
PBS 
+ 5 % (v/v) macrophage medium 
human 
macrophages 
proliferation medium RPMI 1640 
+ 5 % (v/v) FCS (Lot: 105K3396) 
(Sigma-Aldrich, Steinheim) 
+ 1 % (v/v) penicillin/streptomycin/L-glutamine 
+ 0.05 mmol/l 2-mercaptoethanol 
murine T-cells  
and APCs 
red blood cell lysis 
buffer 1x 
10x Lysing buffer BD Pharm lyse 
diluted 1:10 with water 
all murine cells 
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medium composition application 
wash medium RPMI 1640 
+ 5 % (v/v) FCS (Lot: 0434H)  
(Biochrom, Berlin) 
+ 1 % (v/v) penicillin/streptomycin/L-glutamine 
+ 0.05 mmol/l 2-mercaptoethanol
murine T-cells 
and APCs 
 
 
3.1.5 Proteins 
 
Table 4: Proteins used for cell culture or as ELISA standard in this study. 
protein application origin 
mIFN-γ ELISA self-prepared standard from cell culture 
supernatants 
mitomycin C APCs Sigma-Aldrich (Steinheim) 
prostaglandin E2 (PGE2) mDC culture Cayman Chemical (Ann Arbor, MI, USA) 
rhGM-CSF human macrophage 
culture 
Leukine 
rhGM-CSF iDC culture CellGenix (Freiburg) 
rhIL-1 mDC culture Peprotech (Hamburg) 
rhIL-4 iDC culture CellGenix (Freiburg) 
rhM-CSF human macrophage 
culture 
R&D Systems (Wiesbaden) 
rhTNF- mDC culture Peprotech (Hamburg) 
rmGM-CSF BMDC culture R&D Systems (Wiesbaden) 
rmIL-2 ELISA Peprotech (Hamburg) 
rmIL-4 ELISA Peprotech (Hamburg) 
rmIL-6 ELISA BD Biosciences (Heidelberg) 
rmIL-10 ELISA BD Biosciences (Heidelberg) 
rmIL-17A ELISA Peprotech (Hamburg) 
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3.1.6 Antibodies 
 
3.1.6.1 Primary antibodies 
 
Table 5: Primary antibodies used in this thesis. 
antibody clone application origin 
anti-CD36 antibody JC63.1 blocking abcam  
(Cambridge, UK) 
anti-chicken egg albumin 
(mouse IgG1) 
OVA-14 ELISA Sigma-Aldrich 
(Steinheim) 
anti-dinitrophenyl antibody 
(mouse IgE) 
SPE-7 ELISA Sigma-Aldrich 
anti-EEA-1 rabbit pAb polyclonal immunocytochemistry 
(ICC) 
Merck Calbiochem 
(Darmstadt) 
anti-human CD206 
(MMR) PE 
19.2 flow cytometry eBioscience 
(Frankfurt a.M.) 
anti-human CD36 FITC NL07 flow cytometry eBioscience 
anti-human CD80 (B7-1) PE 2D10.4 flow cytometry eBioscience 
anti-human CD86 (B7-2) PE IT2.2 flow cytometry eBioscience 
anti-human HLA-DR PE L243 flow cytometry eBioscience 
anti-human SR-AI/MSR1-PE 351615 flow cytometry R&D Systems 
(Wiesbaden) 
anti-mouse CD11b PE M1/70 flow cytometry eBioscience 
anti-mouse CD11c APC N418 flow cytometry eBioscience 
anti-mouse CD16/CD32 
purified 
93 flow cytometry eBioscience 
anti-mouse CD4 PE GK1.5 flow cytometry eBioscience 
anti-mouse CD80 (B7-1) 
FITC 
16-10A1 flow cytometry eBioscience 
anti-mouse CD86 
(B7-2) FITC 
GL1 flow cytometry eBioscience 
anti-mouse CD8a PE 53-6.7 flow cytometry eBioscience 
anti-mouse IFN-γ purified R4-6A2 ELISA eBioscience 
anti-mouse IFN-γBiotin XMG1.2 ELISA eBioscience 
anti-mouse IL-17A Biotin eBio17B7 ELISA eBioscience 
anti-mouse IL-17A purified eBio17CK15A5 ELISA eBioscience 
anti-mouse IL-4 Biotin BVD-24G2 ELISA eBioscience 
anti-mouse IL-4 purified 11B11 ELISA eBioscience 
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antibody clone application origin 
anti-mouse IL-6 Biotin MP5-32C11 ELISA eBioscience 
anti-mouse IL-6 purified MP5-20F3 ELISA eBioscience 
anti-mouse MHC Class II 
(I-A/I-E) FITC 
M5/114.15.2 flow cytometry eBioscience 
anti-mouse/rat CD40 FITC HM40-3 flow cytometry eBioscience 
Biotin anti-mouse IL-2 JES6-5H4 ELISA BioLegend (Fell) 
Biotin rat anti-mouse IgE R35-118 ELISA BD Pharmingen 
(Heidelberg) 
goat anti-mouse IgG1-HRP polyclonal ELISA Invitrogen 
(Darmstadt) 
goat anti-mouse IgG2a-HRP polyclonal ELISA Invitrogen 
mouse anti-CEL 4F5 ELISA kind gift of  
Prof. Ryoji Nagai  
(Tokyo, Japan) 
mouse anti-CML 6D12 ELISA kind gift of  
Prof. Ryoji Nagai 
mouse anti-GA-pyridine 2A2 ELISA kind gift of  
Prof. Ryoji Nagai 
mouse IgG1  
isotype control PE 
P3.6.2.8.1 flow cytometry eBioscience 
mouse IgG2a 
isotype control PE 
eBM2a flow cytometry eBioscience 
mouse IgG2b  
isotype control PE 
eBMG2b flow cytometry eBioscience 
mouse IgM 
isotype control FITC 
11E10 flow cytometry eBioscience 
normal mouse IgG polyclonal immunocytochemistry Santa Cruz 
(Heidelberg) 
purified anti-mouse IL-2 JES6-1A12 ELISA BioLegend (Fell) 
rabbit IgG  
isotype control FITC 
polyclonal flow cytometry eBioscience 
rat IgG1 isotype control FITC eBRG1 flow cytometry eBioscience 
rat IgG2a   
isotype control FITC 
eBR2a flow cytometry eBioscience 
rat IgG2b   
isotype control FITC 
eB149/10H5 flow cytometry eBioscience 
SR-BI antibody 
[DyLight488] 
polyclonal flow cytometry Novus Biologicals 
(Cambridge, UK) 
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3.1.6.2 Secondary antibodies 
 
Table 6: Secondary antibodies used in this thesis. 
antibody application origin 
anti-mouse IgG-HRP ELISA Sigma-Aldrich 
(Steinheim) 
anti-mouse IgA-FITC flow cytometry abcam (Cambridge, UK) 
AlexaFluor®488 goat anti-rat IgG (H+L) flow cytometry Invitrogen  
(Darmstadt) 
Cy3-goat F(ab’) fragment anti-rabbit IgG immunocyto-
chemistry 
Jackson ImmunoResearch 
(Suffolk, UK) 
Streptavidin-HRP ELISA eBioscience 
(Frankfurt a.M.) 
 
 
3.1.7 Mice 
 
Table 7: Mice strains used in this thesis. 
genotype short form genetic 
background 
reference 
BALB/c   wild type (wt)  
C57BL/6J   wt  
C.Cg-Tg(DO11.10)10Dlo/J DO11.10 BALB/c Murphy et al.(86) 
C57BL6-Tg(TcraTcrb)1100Mjb/J OT-I C57BL/6 Hogquist et al.(87) 
B6.Cg-Tg(TcraTcrb)425Cbn/J OT-II C57BL/6 Barnden et al.(88) 
B6.Cg-Msr1
tm1Csk
/J SR-A
-/-
 C57BL/6 Suzuki et al.(89) 
 
BALB/c mice and C57BL/6J mice were purchased from Charles River Laboratories (Kisslegg). 
Breeding pairs of the genetically modified mice were originally bought at Jackson Laboratories (Bar 
Harbour, ME, USA) and bred in the mouse breeding facility of the Paul-Ehrlich-Institut according to 
the German legislation. 
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3.1.8 Software 
The analysis of the data, excluding flow cytometric analyses, was done using the program GraphPad 
Prism 5.04 (GraphPad Software Inc., La Jolla, CA, USA) 
The data generated by the flow cytometers with BD FACSDiva Software v6.1.3 (BD Biosciences, 
Heidelberg) were exported and analyzed with FlowJo v7.6.3 (TreeStar Inc., Ashland, OR, USA). 
SoftMax Pro 5.2 (Molecular Devices Corp., Sunnyvale, CA, USA) was used for measurement of plates 
at the ELISA reader. 
Densitometric analysis of Coomassie-stained gels after SDS-PAGE was performed with Totallab 
TL120 v2006. 
Statistical analysis of the data was performed with IBM SPSS statistics (IBM, Chicago, IL, USA) and 
either analysis of variance followed by Dunnett’s test or for data of individual mice Mann-Whitney 
test was used. A p value below 0.05 was considered significant. 
 
 
3.2 Methods 
 
3.2.1 Preparation of AGE-OVA and AGE-BSA 
Crude glycated ovalbumin (AGE-OVA) and crude glycated bovine serum albumin (AGE-BSA) were 
prepared using a protocol established by Gasic-Milenkovic et al.(90) In detail, 1 mmol/l endotoxin-free 
OVA (Seikagaku Corporation, Tokyo, Japan) or 1 mmol/l BSA (Sigma-Aldrich, Steinheim) were 
incubated with 1 mol/l glucose (VWR, Darmstadt) in 100 mmol/l sodium phosphate buffer for 
six weeks at 50 °C. Afterwards, excess glucose was removed by extensive dialysis against PBS. OVA 
or BSA incubated under the same conditions but without glucose served as controls and is referred to 
as incubated OVA (inc. OVA) or incubated BSA (inc. BSA) in the following. 
 
100 mmol/l sodium phosphate buffer pH 7.4:      19 ml phosphate buffer A 
 +  81 ml phosphate buffer B 
 + 100 ml H2O 
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3.2.2 Selective modification of OVA with distinct glycation structures 
The selective modification of endotoxin-free OVA with the glycation structures CEL, CML, MG-H1 
or pyrraline was performed by Dr. Anne Wellner from Technische Universität (TU) Dresden.  
Modification of OVA with CEL or CML as well as arginine modification with MG-H1 was performed 
according to Glorieux et al.(91) Briefly, to a solution of 20 mg/ml OVA in 0.2 mol/l sodium phosphate 
buffer 15 mol pyruvic acid per mol lysine for carboxyethylation or 5 mol glyoxylic acid per mol lysine 
for carboxymethylation were added. After adjusting the pH to 7.4 with 0.5 mol/l NaOH and addition of 
41 mmol NaBH3CN for CEL- or 8.8 mmol NaBH3CN for CML-modification, respectively, the 
solution was heated for 20 h at 40 °C. 
Arginine modification with MG-H1 was carried out by incubating a solution of 10 mg/ml OVA and 
2 mol methylglyoxal (MGO) per mol arginine residues in OVA in 0.067 mol/l sodium phosphate 
buffer for 30 min at 40 °C.  
The method for modification of OVA with pyrraline was established by Henle and Bachmann.(92) 
Briefly, 4 mg/ml OVA were dissolved in 0.1 mol/l sodium acetate buffer and 3-desoxyglucosulose 
(3-DG) was added, resulting in a molar ratio of 3-DG to lysine of 4:1. The solution was lyophilized 
and the mixture was incubated in a dry state at 70 °C for 10 min, 30 min or 4 h, respectively. 
Before analysis, all samples were extensively dialyzed against water and lyophilized. Overall 
modification of lysine and arginine residues was assessed with amino acid analysis as described by 
Henle et al.(93, 94) This method was also applied for determining the level of MG-H1 conjugated to 
OVA. The levels of CEL or CML were determined with gas chromatography-mass spectrometry 
(GC-MS) analysis after acid hydrolysis as described by Wellner et al.(95) The glycation structure 
pyrraline was detected using reversed phase high performance liquid chromatography with diode array 
detector (RP-HPLC/DAD) as described by Förster et al.(96) 
 
 
3.2.3 Determination of protein concentration with BCA 
The principle for quantification of proteins using bicinchoninic acid (BCA) is based on the Biuret 
reaction.(97) In alkaline solution Cu
2+
 ions are reduced by proteins to Cu
+
 ions. In a second step, Cu
+
 
ions form violet coloured complexes with BCA, which can be detected using a photometer.(97) 
The protein concentration was determined using BCA Protein Assay Kit (Thermo Scientific, 
Nidderau) according to the manufacturer’s instructions. If necessary, protein and standard samples 
were diluted in PBS. Then, a volume of 25 µl per sample was transferred to a 96-well microtiter plate 
(NUNC, Wiesbaden) in duplicate. The working reagent was prepared by mixing 50 parts of solution A 
and 1 part of solution B. 200 µl working reagent were added to the samples and the plate was 
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incubated for 30 min at RT in the dark on an orbital shaker. The absorbance at a wavelength of 562 nm 
was measured by an ELISA reader. 
 
Solution A: sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartrate in 
0.1 mol/l NaOH 
Solution B:  4 % (w/v) Cu2SO4 in H2O 
 
 
3.2.4 Gel electrophoresis 
The basic principle of gel electrophoresis is the separation of different molecules by means of their 
different electrophoretic mobility.(97) The most commonly used technique for the separation of 
proteins is sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), which separates 
protein-SDS complexes according to their molecular weight.(97) Here, the  discontinuous SDS-PAGE 
without acrylamide gradient first described by Laemmli was used.(98) 
The protein samples were loaded with SDS by incubation of the sample containing SDS loading buffer 
for 3 min at 95 °C. The cooled samples were shortly centrifuged before loading on the gel, which 
consisted of a 4.5 % stacking gel and either 7.5 % or 10 % separation gels. Electrophoresis was carried 
out at a constant voltage of 100 V in SDS running buffer. The gels were washed in water for 1 h to 
remove the SDS, which would be interfering with the dye Coomassie Brilliant Blue. The gels were 
stained with GelCode Blue Stain Reagent (Thermo Scientific, Nidderau) for 2 h. Unbound dye was 
removed by washing the gels in water for at least 1 h. Afterwards, the gels were scanned for 
documentation. 
 
7.5 % separation gel: 9.0 ml H2O 
 4.5 ml acrylamide (Rotiphorese® Gel 40; Carl Roth, Karlsruhe) 
 4.5 ml separation gel buffer 
 80 µl 10 % (w/v) ammoniumpersulphate (APS) 
 15 µl N,N,N’,N’-tetramethylethylenediamine (TEMED) 
 
10 % separation gel: 7.5 ml H2O 
 6 ml acrylamide (Rotiphorese® Gel 40) 
 4.5 ml separation gel buffer 
 80 µl 10 % (w/v) APS 
 15 ml TEMED 
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4.5 % separation gel: 3.6 ml H2O 
 0.9 ml acrylamide (Rotiphorese® Gel 40) 
 1.5 ml stacking gel buffer 
 20 µl 10 % (w/v) APS 
 15 µl TEMED 
 
Molecular weight marker: PageRuler Plus Prestained Protein Ladder (#26619; Thermo Scientific, 
Nidderau) 
 PageRuler Prestained Protein Ladder (#26616; Thermo Scientific) 
 
 
3.2.5 Enzyme-linked immunosorbent assay (ELISA) 
The basic principle of an ELISA is the detection of a specific protein or structure via antigen-antibody 
interaction.(99) In the indirect ELISA system, the antigen is bound to the surface of an ELISA 
microtiter plate and then detected by an antigen-specific primary antibody together with a matching 
enzyme-conjugated secondary antibody.(99) In the final step, an enzyme, mainly peroxidases are used, 
converses a colorimetric substrate for detection by optical means.(99) 
The detection of a specific antigen from a crude mixture of proteins can be done using a sandwich 
ELISA, where the plate is coated with an antigen-specific capture antibody.(99) In the next step, the 
antigen is applied and afterwards, it is detected as already described for the indirect ELISA.(99) 
 
All incubation steps were carried out at RT and 80 rpm (rounds per minute) on a shaker unless stated 
otherwise. Between the incubation steps, the plates were washed three times with 150 µl/well ELISA 
washing buffer. 
 
 
3.2.5.1 Detection of AGE-structures with ELISA 
For the detection of AGE-structures with ELISA according to Ilchmann et al., ELISA plates 
(Microlon600; greiner bio-one, Frickenhausen) were coated with 50 µl/well of a 5-fold dilution series 
(1 mg/ml to 0.5 ng/ml) of modified OVAs in ELISA coating buffer at 4 °C overnight (o/n).(71) 
Unbound binding sites of the plates were blocked by incubation with 100 µl/well ELISA blocking 
buffer for 1 h. Afterwards, the plates were incubated for 2 h with 50 µl/well of 1 µg/ml primary 
antibody recognizing the glycation structure in ELISA assay buffer. Available were mouse monoclonal 
antibodies (mAb) raised against the glycation structures CEL, CML or glycolaldehyde-pyridine 
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(GA-pyridine). These primary antibodies were detected by incubation of the plate with 50 µl/well 
horseradish peroxidase (HRP-)conjugated anti-mouse IgG diluted 1:20,000 in ELISA assay buffer for 
1 h. Subsequently, 100 µl/well of substrate solution was added and the plates were incubated for up to 
30 min on the shaker in the dark. The substrate oxidized by the peroxidase was 
3,3’,5,5’-tetramethylbenzidine (TMB) (555214; BD Biosciences, Heidelberg). The enzymatic reaction 
was stopped by addition of 50 µl/well of 0.5 mol/l H2SO4. The absorbance at a wavelength of 450 nm 
and a reference wavelength of 630 nm was measured by an ELISA reader. For evaluation, the reduced 
absorbance, i.e. the difference of the absorbance values at 450 nm and 650 nm, was used. 
 
  
3.2.5.2 Detection of OVA-specific IgE, IgG1 and IgG2a antibodies in the sera of mice 
Detection of OVA-specific IgE, IgG1 or IgG2a antibodies in sera was performed using a sandwich 
ELISA system. ELISA plates were coated with 0.1 µg/ml native OVA in ELISA coating buffer o/n at 
4 °C. Wells for the IgE standard curve were coated o/n at 4 °C with 0.5 µg/ml purified anti-mouse IgE 
mAb. After blocking of free binding sites by incubation for 1 h with 100 µl/well ELISA blocking 
buffer, the plates were incubated with 50 µl/well sample for 2 h. Samples were sera from mice 
sensitized with OVA or from sensitized and EW-diet fed mice diluted in ELISA assay buffer or 
standard solutions. A 2-fold dilution series in ELISA assay buffer ranging from 1 U/ml to 2 mU/ml of 
mouse anti-dinitrophenyl IgE was applied for the IgE standard curve. The standard curves for IgG1 
and IgG2a were prepared using a 2-fold dilution series in ELISA assay buffer ranging from 
62.5 mU/ml to 0.12 mU/ml of mouse anti-OVA IgG1 mAb. Afterwards, the plates were incubated for 
1 h with 50 µl/well of Biotin-anti-mouse IgE (1:1000), HRP-anti-mouse IgG1 (1:4000) or 
HRP-anti-mouse IgG2a (1:4000) diluted in ELISA assay buffer as primary antibodies, respectively. 
Incubation with Streptavidin-HRP diluted 1:2000 in ELISA assay buffer for 30 min was only 
necessary for the detection of IgE antibodies. 
Substrate reaction and the following steps were performed as already described in chapter 3.2.5.1. 
 
 
3.2.5.3 Detection of cytokines in cell culture supernatants 
Cytokines in cell culture supernatants were detected using a sandwich ELISA system with compatible 
antibody pairs offered by the manufacturers. ELISA plates were coated o/n at 4 °C with 50 µl/well of 
0.5 µg/ml capture antibody, a purified antibody specific for the respective cytokine, in ELISA 
coating buffer. Free binding sites of the plates were blocked by incubation with 100 µl/well ELISA 
blocking buffer for 1 h. As standards for the quantification of the cytokine levels a 2-fold dilution 
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series ranging from 4 ng/ml to 8 pg/ml of the respective recombinant cytokine in medium was 
prepared. The plates were incubated for 2 h with 50 µl/well sample in duplicate, i.e. (un)diluted cell 
culture supernatants or standard dilution series. The captured cytokine was detected by incubation of 
the plates for 1 h with 50 µl/well of 0.5 µg/ml Biotin-conjugated cytokine-specific antibody in ELISA 
assay buffer. Subsequently, the plates were incubated with 50 µl/well Streptavidin-HRP diluted 1:4000 
in ELISA assay buffer for 30 min in the dark. 
Substrate reaction and the following steps were performed as already described in chapter 3.2.5.1. 
 
 
3.2.6 Measurement of protein secondary structure with circular dichroism spectroscopy 
Circular dichroism spectroscopy (CD-spectroscopy) is based on the differential absorbance of circular 
polarized light by optic active substances, like proteins.(97) The secondary structure elements of 
proteins show different absorbance of the left and the right circular polarized component of circular 
polarized light.(97) The difference of both absorbance values, which is called, ellipticity, is measured 
by a CD-spectrometer as a function of the wavelength.(97) 
Salt was removed by dialyzing the sample o/n against plenty 10 mmol/l phosphate buffer pH 7.4. After 
initialization of the spectrometer, baseline correction was performed by measuring the spectrum of 
10 mmol/l phosphate buffer pH 7.4 in the range of 185 nm to 255 nm. Then a fast test measurement of 
the sample was run to check that salt has been efficiently removed and protein concentration was 
appropriate. For the regular measurement, the sample was scanned ten times with the settings listed 
below in table 8. 
 
Table 8: Settings used for measurement of CD-spectra. 
parameter setting 
start wavelength 255 nm 
end wavelength 185 nm 
scanning mode continuous 
scanning speed slow: 50 nm/min 
fast test: 500 nm/min 
bandwidth 1.0 nm 
accumulation 10 (or 1 for preliminary test) 
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The data was evaluated by calculating the mean residual ellipticity (MRW) according to the formula 
below and plotted against the wavelength. 
 
dcN
MRW



100
 
 
: measured ellipticity in mdeg 
N: number of amino acid residues 
c: protein concentration in mmol/l 
d: path length in cm 
 
10 mmol/l phosphate buffer pH 7.4: 19.7 ml CD-buffer A 
 80.3 ml CD-buffer B 
 ad 1 l with H2O 
 
 
3.2.7 Labelling of proteins with FITC 
The uptake of an antigen by dendritic cells and the subsequent antigen processing inside the cell can 
only be elucidated if the antigen is labelled with a fluorophore. The fluorophore fluorescein 
isothiocyanate (FITC) can be bound to proteins by formation of a stable thiourea bond between free 
amino residues of the protein and the isocyanate group of the dye. The molar ratio of bound FITC to 
the protein, the molar FITC/protein-ratio, can be easily determined by absorbance measurements and 
was of great interest, because for the comparison of the antigen uptake of different proteins the 
FITC/protein-ratio in all samples needs to be similar. 
The labelling of native OVA, inc. OVA, all modified OVA samples, native BSA, inc. BSA and 
AGE-BSA with FITC was performed with the FluoroTag FITC Conjugation Kit (FITC1; 
Sigma-Aldrich, Steinheim).  
One vial of FITC was reconstituted in 0.1 mol/l sodium carbonate buffer pH 9.0 and solutions with 
different FITC concentrations shown in table 9 were prepared. For the small scale labelling procedure 
50 µl FITC-solution were added dropwise to 200 µl of protein solution (5 mg/ml in 0.1 mol/l sodium 
carbonate buffer pH 9.0). The reaction mixture was incubated for 2 h at RT in the dark. The sample 
was applied to an equilibrated Sephadex G25M column for the separation of the labelled protein and 
excess dye. The flow through was collected followed by elution of the labelled protein with PBS in ten 
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fractions à 250 µl. During elution two distinct yellow bands were visible, the lower one containing the 
labelled protein and the upper one the unreacted dye.  
The absorbance of the fractions at a wavelength of 280 nm was measured to determine protein content. 
Fractions with an absorbance value above 0.2 were pooled and the molar FITC/protein-ratio was 
determined. The samples were stored for several days at 4 °C in solution or lyophilized aliquots were 
stored at -80 °C for long-term storage. 
 
Table 9: Prepared FITC-solutions for the labelling reaction. 
FITC concentration 0.1 mol/l 
sodium carbonate buffer pH 9.0 
reconstituted FITC 
(20:1) 
20:1 2 ml 1 vial 
10:1 500 µl 500 µl 
5:1 750 µl 250 µl 
 
Determination of the molar FITC/protein-ratio: 
For the determination of the molar FITC/protein-ratio with the formula below the absorbance of the 
labelled proteins at 280 nm and at 495 nm was measured. 
 
  495280
495
495280
%1.0
495
%1.0
280495
35.035.0 AA
A
C
AAF
PA
M
M
protein
FITC
FITC
protein




  
 
Where: 
%1.0
495
%1.0
280
F
P
M
M
C
FITC
protein
  is a protein-specific absolute term. 
 
Mprotein is the molecular weight of the protein. 
MFITC: is the molecular weight of FITC and is 389 g/mol. 
%1.0
280P : is the absorbance of 1 mg/ml protein at 280 nm and is 0.686 for OVA or 0.6 for BSA. 
1.0
495F : is the absorbance of bound FITC at 495 nm at pH 13.0 and is 195. 
A495: measured absorbance at 495 nm. 
A280: measured absorbance at 280 nm. 
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3.2.8 Cell culture 
All cell culture works were carried out under sterile conditions in a laminar flow cabinet. The cells 
were incubated at 37 °C with 5 % CO2 and a relative humidity of 80 % if not stated otherwise. 
 
 
3.2.8.1 Culture of murine cells 
 
3.2.8.1.1 Preparation of murine bone marrow-derived dendritic cells (BMDCs) 
The sacrificed mice were disinfected using 70 % ethanol. The bones were carefully removed from the 
hind legs. Using a fresh pair of forceps, the bones were shortly disinfected in 70 % ethanol and 
afterwards washed in RPMI 1640. The ends of the bones were cut off with a fresh scissor and the bone 
marrow was rinsed out using a syringe with a 26G needle filled with 5 ml DC medium. A single cell 
suspension was prepared by pipetting and then given through a 70 µm cell strainer (BD Biosciences, 
Heidelberg). The cells of one leg were pooled and centrifuged at 1100 rpm and 4 °C for 6 min. All 
following centrifugation steps were carried out with these settings. The supernatant was discarded and 
the pellet was loosened by shaking. Lysis of erythrocytes was performed by addition of 1.5 ml red 
blood cell lysis buffer 1x per leg followed by incubation for 1 min at RT. To stop lysis, 10 ml 
DC medium were added and the cells were centrifuged. The cells were washed twice with 
DC medium. In a final volume of 5 ml DC medium 5 106 cells were seeded in a T25 cell culture flask 
(NUNC, Wiesbaden) and 100 ng/ml rmGM-CSF (recombinant murine granulocyte macro-
phage-colony stimulating factor) were added. 
The media needed to be exchanged at day 3, day 6 and day 7 of culture. 
The differentiated bone marrow-derived dendritic cells (BMDCs) were harvested on day 8 of culture 
using a cell scraper (TPP, Trasadingen, CH). The cells were washed once with DC medium and the 
cell number was determined. 
 
 
3.2.8.1.2 Assessment of BMDC maturation 
The maturation of BMDCs upon antigen stimulation was assessed by culturing 1 106 BMDCs from 
C57BL/6 mice, generated as described in chapter 3.2.8.1.1, in the presence of 50 µg/ml antigen in a 
cell culture plate (greiner bio-one, Frickenhausen) for 20 h. Antigens used in this assay were all forms 
of OVA as well as 1 µg/ml LPS, which served as positive control. The cell culture supernatants were 
collected for cytokine measurement with ELISA according to chapter 3.2.5.3 and the cells were 
stained for expression of the co-stimulatory molecules CD40, CD80, CD86 as well as for MHC class II 
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molecules as described in chapter 3.2.9.2. Afterwards, the cells were stained for the DC cell surface 
markers CD11b and CD11c according to chapter 3.2.9.4. 
 
 
3.2.8.1.3 Assessment of antigen uptake by BMDCs with flow cytometric analysis 
BMDCs from C57BL/6 mice or B6.Cg-Msr1 mice were prepared as described in chapter 3.2.8.1.1 and 
for this assay 1 106 cells in a volume of 200 µl were seeded into a 24-well cell culture plate (greiner 
bio-one, Frickenhausen). After the addition of 200 µl of antigen solution, the cells were incubated for 
15 min at 37 °C. As antigens FITC-labelled forms of all OVA samples as well as FITC-labelled native 
BSA, inc. BSA and AGE-BSA were used. Then, the cells were scraped and transferred into a 
FACS-tube (BD Biosciences, Heidelberg). The cell culture plate was washed twice with PBS, the 
washing solution was added to the respective cells and then the cells were centrifuged at 1100 rpm and 
4 °C for 5 min. After blocking of Fc-receptor binding according to chapter 3.2.9.1, the cells were 
stained for the surface markers CD11b and CD11c as described in chapter 3.2.9.4 and analyzed with 
flow cytometry on the same day. 
The contribution of several receptors in antigen uptake was analyzed with specific ligands inhibiting 
antigen-binding. Therefore, BMDCs were pre-incubated with the respective inhibitor listed in table 10 
for 30 min at 37 °C before addition of the antigen. 
 
Table 10: Receptors, their inhibitors and the respective inhibitor concentration used to elucidate receptor 
contribution to antigen uptake. 
receptor inhibitor amount of inhibitor used 
CD36 blocking antibody 2 µg/ml 
galectin-3 lactose 150 mmol/l 
MR (CD206) mannan 3 mg/ml 
SR-BI phosphatidylserine 100 µmol/l 
SR-BI BLT-1 10 µmol/l or 1 µmol/l 
 
 
3.2.8.1.4 Cell preparation for analysis with a confocal microscope 
A confocal microscope, also called laser scanning microscope (LSM), is used to investigate 
(co-)localisations of proteins inside cells.(97) Before microscopic analysis, the proteins are directly 
conjugated with a fluorescent dye or stained directly or indirectly with antibodies labelled with a 
fluorophore.(97) 
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In an LSM, a high resolution is achieved by focussing the laser light in one point of the sample.(97) 
The emitted fluorescence of the target passes through a confocal pinhole before reaching the detector, 
which is usually a photomultiplier.(97) Confocal means that the pinhole is in the conjugate plane of the 
focus point in the sample.(97) Hence, emitted light outside the focus plane is rejected by the pinhole 
and does not reach the detector.(97) The images are generated by point-to-point scattering of the 
sample followed by a reconstruction of the detector signals by a computer.(97) 
For cell analysis with a confocal microscope, 12 mm round cover slips (Carl Roth, Karlsruhe) were 
placed in a 24-well cell culture plate and 400 µl 1.25 106 BMDCs/ml in DC medium, were added. 
During 1 h incubation at 37 °C, the cells could adhere on the cover slips. Afterwards, fresh 
DC medium was added and BMDCs were incubated with 10 µg/ml of FITC-labelled OVA sample for 
15 min at 37 °C. All following steps were carried out in the dark at RT and between all single steps the 
cells were washed three times with plenty PBS. The cells were fixed after washing by incubation for 
20 min with 4 % (w/v) paraformaldehyde (PFA) (Thermo Scientific, Nidderau) in PBS. Then blocking 
and permeabilization was performed by incubation of the cells for 1 h in permeabilization-buffer. The 
cells were incubated with 5 µg/ml primary antibody for 1 h and afterwards with 5 µg/ml secondary 
antibody for 30 min, both diluted in ICC-assay buffer. For staining of endosomal compartments, 
polyclonal rabbit anti-early endosomal antigen-1 (EEA-1) IgG together with Cy3-goat F(ab’) fragment 
anti-rabbit IgG as secondary antibody were used. The nucleus was stained by incubation of the cells 
with 0.125 µg/ml 4’,6-diamidino-2-phenylindole (DAPI) in ICC-assay buffer for 7 min. The cover 
slips were mounted with fluorescence mounting medium (S3023; DAKO, Hamburg) on SuperFrost® 
microscope slides (VWR, Darmstadt). After drying, the slides were stored at 4 °C in the dark until 
analysis with a LSM 510 (Carl Zeiss, Jena). 
 
 
3.2.8.1.5 Preparation of splenocyte or lymph node cell suspension for T-cell isolation 
The sacrificed mice were disinfected in 70 % ethanol. The spleen or the lymph nodes (LN) of interest 
were removed and placed in a petri dish containing wash medium. The cells were mechanically 
released by pressing the organ with the plunger of a syringe. The cell suspension was filtered through a 
70 µm cell strainer and centrifuged. All centrifugation steps were carried out at 1300 rpm and 4 °C for 
10 min. After centrifugation, red blood cell lysis was carried out for spleens only by adding 1.5 ml red 
blood cell lysis buffer 1x per spleen and incubating for 1 min to 2 min at RT. The lysis was stopped by 
addition of 10 ml wash medium and the cells were centrifuged. Splenocytes and LN cells were washed 
twice with 10 ml wash medium, respectively, and afterwards resuspended in 5 ml MACS-buffer before 
determining the cell number. 
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3.2.8.1.6 Magnetic separation of CD4+ or CD8+ T-cells 
The basic principle of magnetic cell sorting (MACS) is the separation of magnetically labelled cells 
from unlabelled ones. Therefore, cells become labelled with specific magnetic beads before the actual 
separation in a strong magnetic field using a special column is performed. The principle of positive 
selection was applied for CD4
+
 T-cell separation, i.e. CD4
+
 T-cells were retained in the magnetic field, 
whereas the flow-through and washing fractions contained non-CD4
+
 cells. For elution of the labelled 
CD4
+
 T-cells, the column needed to be removed from the magnetic field. The opposite, namely 
negative selection, was used for CD8
+
 T-cell separation. 
 
For T-cell isolation, either splenocyte or LN cell suspension (see 3.2.8.1.5) was centrifuged at 
1300 rpm at 4 °C for 10 min and the supernatant was completely removed by pipetting. 
Labelling of CD4
+
 T-cells was performed by resuspending the cells in 90 µl MACS-buffer per 
10
7
 cells and addition of 10 µl CD4 (L3T4) MicroBeads (130-049-201; Miltenyi Biotec, Bergisch-
Gladbach) per 10
7
 cells. The mixture was incubated for 15 min in the fridge. 
For CD8
+
 T-cell isolation, the CD8a
+
 T-cell isolation kit (130-090-859; Miltenyi Biotec, Bergisch-
Gladbach) was used. Non-CD8
+
 T-cells were labelled by resuspension of splenocytes in 40 µl 
MACS-buffer per 10
7
 cells followed by incubation with 10 µl Biotin-Antibody Cocktail per 10
7
 cells 
for 10 min in the fridge. After addition of 30 µl MACS-buffer per 10
7
 cells and 20 µl Anti-Biotin 
MicroBeads per 10
7
 cells, the cells were incubated for additional 15 min in the fridge. 
The labelling reaction was stopped by addition of 1 ml to 2 ml MACS-buffer per 10
7
 cells and 
centrifugation at 1300 rpm and 4 °C for 10 min. The supernatant was completely removed by pipetting 
and the cells were resuspended in 500 µl MACS-buffer per 10
8
 cells. The suspension was applied to an 
equilibrated MACS LS column (130-042-401; Miltenyi Biotec, Bergisch-Gladbach) placed in the 
strong magnetic field of a QuadroMACS Separator (130-080-976; Miltenyi Biotec, 
Bergisch-Gladbach). The column was washed with plenty MACS-buffer. The flow-through and 
washing fractions contained unlabelled CD8
+
 T-cells. For collection of CD4
+
 T-cells, the column was 
removed from the magnetic field and labelled CD4
+
 T-cells were eluted with 5 ml MACS-buffer. After 
washing once with cell culture medium, the cells were used in the respective assays. 
The isolated CD4
+
 T-cells and CD8
+
 T-cells had a purity of over 90 % as was determined by flow 
cytometry as described in chapter 3.2.9. 
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3.2.8.1.7 Co-culture of BMDCs with OVA-specific CD4+ T-cells 
This assay was used to assess the CD4
+
 T-cell immunogenicity of the modified OVAs. BMDCs were 
prepared as described in chapter 3.2.8.1.1 and OVA-specific OT-II-derived or DO11.10-derived 
CD4
+
 T-cells were prepared according to chapter 3.2.8.1.6. In the wells of a 96-well flat bottom cell 
culture plate (NUNC, Wiesbaden) 1.6 105 BMDCs/ml and 8 105 CD4+ T-cells/ml were seeded and 
antigen solution was applied. The cells were stimulated with final concentrations of 2 µg/ml or 
20 µg/ml of all modified OVAs including native OVA and inc. OVA as controls. Cells treated with 
medium only served as negative control. 
Cell culture supernatants after 24 h and 72 h incubation were used for the determination of cytokine 
expression by ELISA as described in chapter 3.2.5.3 
 
 
3.2.8.1.8 Co-culture of BMDCs with OVA-specific CD8+ T-cells 
A co-culture of C57BL/6-derived BMDCs with OVA-specific OT-I-derived CD8
+
 T-cells was used to 
investigate the CD8
+
 T-cell immunogenicity of the modified OVAs. 
The method of Burgdorf et al. was adapted with minor modifications.(59) Briefly, BMDCs, generated 
as described in chapter 3.2.8.1.1, were stimulated with 10 µg/ml LPS for 2 h at 37 °C. Afterwards, the 
cells were scraped, washed three times with DC medium and 6.25 105 BMDCs/ml were seeded into a 
96-well round bottom cell culture plate (NUNC, Wiesbaden). Then the antigen solution, which has 
already been described in chapter 3.2.8.1.7, was added resulting in a final concentration of 20 µg/ml or 
200 µg/ml of OVA and BMDCs were primed with antigen for 3 h at 37 °C. The cells were washed 
three times with plenty PBS (prewarmed to 37 °C in a water bath) and afterwards, the cells were re-
equilibrated in 100 µl/well warm DC medium (37 °C). To this suspension, 1.25 106 CD8+ T-cells/ml, 
isolated according to chapter 3.2.8.1.6, were added. The resulting co-culture was incubated at 37 °C 
for 20 h to 72 h. Cytokine expression in the cell culture supernatants was determined by ELISA as 
described in chapter 3.2.5.3. 
 
 
3.2.8.1.9 Assessment of CD4+ T-cell proliferation using CFSE 
Staining of cells with carboxyfluorescein diacetate succinimidyl ester is often used for analysis of cell 
proliferation.(99) The molecule is colourless extracellular and after diffusion into cells it is 
transformed into highly fluorescent carboxyfluorescein succinimidyl ester (CFSE).(99) This 
fluorescent dye is retained inside the cells by formation of conjugates with intracellular amines, mainly 
 Materials and Methods 37 
proteins.(99) Upon cell division or proliferation approximately half of the conjugated proteins are 
transferred to the new cell and this can be detected with flow cytometry as shown in figure 5.(99) 
 
 
Figure 5: Mechanism of CFSE division. (A) Schematic illustration of CFSE dilution upon cell division. (B) Example of 
flow cytometric analysis of CFSE-stained proliferating cells. In the histogram, the parent generation (0) and five daughter 
generations are shown. 
 
The proliferation of OVA-specific OT-II-derived or DO11.10-derived CD4
+
 T-cells was analyzed 
using the CellTrace™ CFSE Cell Proliferation Kit (C34554; Life Technologies GmbH, Darmstadt) 
according to the manufacturer’s instructions. Briefly, magnetically separated CD4+ T-cells, prepared as 
described in chapter 3.2.8.1.6, were washed once with 5 ml PBS + 0.1 % (w/v) BSA (Sigma-Aldrich, 
Steinheim). The cell concentration was adjusted to 1 106 cells/ml with PBS + 0.1 % (w/v) BSA and 
2 µl CFSE 5 mmol/l in dimethyl sulphoxide (DMSO) were added per 1 ml cell suspension. The 
mixture was incubated for 10 min at 37 °C in a water bath and the staining reaction was quenched by 
addition of 5 volumes of ice-cold DC medium followed by incubation of the cells for 5 min on ice. The 
cells were washed three times with 10 ml DC medium, respectively. 
For the assessment of CD4
+
 T-cell proliferation, 8 105 CFSE-stained CD4+ T-cells/ml together with 
1.6 105 BMDCs/ml were seeded into a 96-well flat bottom cell culture plate (NUNC, Wiesbaden) and 
the antigen solution was added. As antigens all forms of OVA in a final concentration of 2 µg/ml were 
used. After 96 h incubation, the cells were detached from the plate by short incubation with 25 µl/well 
of EDTA/trypsin at 37 °C followed by addition of 250 µl/well of cold DC-medium. The cells were 
transferred to a FACS tube and 1 ml FACS-buffer was added. Unspecific binding to Fc-receptors of the 
cells was blocked as described in chapter 3.2.9.1. The cells were then stained for CD4 according to 
chapter 3.2.9.2 and analyzed by flow cytometry on the same day. 
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3.2.8.1.10 Assessment of CD4+ T-cell proliferation using [methyl-3H]thymidine 
Proliferation of CD4
+
 T-cells was also assessed by incorporation of the radioactive-labelled nucleotide 
thymidine. 
For this assay, splenic antigen-presenting cells (APCs) were prepared from spleens of naive syngeneic 
mice as described in chapter 3.2.8.1.5 without lysis of the red blood cells. Incubation of 
1 108 splenocytes with 50 µg/ml mitomycin C for 30 min at 37 °C in a water bath inhibited their 
proliferation ability and retained the antigen-presenting capacity. After washing three times with 
proliferation medium, 2 106 APCs/ml were seeded into a 96-well cell culture plate (NUNC, 
Wiesbaden) together with 5 105 CD4+ T-cells/ml, which were isolated as described in chapter 
3.2.8.1.6. The cells were stimulated with 100 µg/ml or 1000 µg/ml of native OVA, Pyr-OVA or 
AGE-OVA. After 72 h of culture, [methyl-
3
H]thymidine (Perkin Elmer, Rodgau) was added to the 
cells at a final concentration of 0.025 nmol/l (equiv. to 0.5 µCi) and the cells were incubated for 
additional 20 h. The cells were transferred onto printed filter mats A (Perkin Elmer, Rodgau) and 
MeltiLex™A melt-on scintillator sheets (Perkin Elmer, Rodgau) for signal amplification were melted 
on. The filter mats were sealed in sample bags (Perkin Elmer, Rodgau), transferred into a cassette and 
the frequency of radioactive-labelled cells was counted by a scintillation counter (1450 Microbeta 
Liquid Scintillation and Luminescence counter; Perkin Elmer, Rodgau). 
 
 
3.2.8.2 Culture of human cells 
 
3.2.8.2.1 Preparation of human dendritic cells 
The preparation of human DCs is divided into two steps, first, the isolation of CD14
+
 monocytes and 
second, the differentiation of monocytes into immature dendritic cells (iDCs).  
For the isolation of human monocytes by Ficoll gradient centrifugation, 15 ml Ficoll were given into a 
50 ml centrifugation tube. The disinfected blood bag was opened and the buffy coat was transferred 
into a T75 cell culture flask. The blood was diluted with PBS up to a volume of 200 ml. Then, Ficoll 
was carefully overlayed with 25 ml of diluted buffy coat. After centrifugation at 900 xg for 20 min 
without brake, different layers were visible as shown in figure 6. The small white one was composed 
of the cells of interest and was carefully transferred into a fresh centrifugation tube. MACS-buffer was 
added up to a volume of 50 ml and the cells were centrifuged at 2000 rpm and 4 °C for 10 min. The 
pellets were resuspended in 5 ml MACS-buffer and the cells of two tubes were pooled. Again, the cells 
were washed by addition of 40 ml MACS-buffer and centrifugation at 1200 rpm and 4 °C for 10 min. 
The pellets were pooled in 20 ml MACS-buffer and the cell number was determined. 
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Figure 6: Schematic picture of Ficoll gradient centrifugation for the separation of human PBMCs from buffy coat. 
 
The yield of the following MACS separation is about 5 %, so 20-times more cells than needed were 
used. The appropriate amount of cells was centrifuged at 300 xg and 4 °C for 10 min. After complete 
removal of the supernatant by pipetting, the cells were resuspended in 40 µl MACS-buffer per 
10
7
 cells. Then 10 µl of CD14 MicroBeads (130-050-201; Miltenyi Biotec, Bergisch-Gladbach) per 
10
7
 cells were added and the mixture was incubated for 15 min in the fridge. The reaction was stopped 
by addition of 500 µl MACS-buffer per 10
7
 cells and centrifugation at 300 xg and 4 °C for 10 min. The 
cells were resuspended in 500 µl MACS-buffer per 10
8
 cells and separation of CD14
+
 cells was 
performed using an autoMACS
®
 Pro Separator (Miltenyi Biotec, Bergisch-Gladbach) and the 
pre-installed method POSSELD. After addition of 4.5 ml human DC medium per 500 µl separated 
cells, the cell number was determined. 
The cells were centrifuged at 1200 rpm and 4 °C for 5 min and afterwards 1 ml of a cell suspension 
with 1 106 cells/ml in human DC medium supplemented with 1000 U/ml rhIL-4 and 1000 U/ml 
rhGM-CSF was given into the wells of a 24-well cell culture plate (greiner bio-one, Frickenhausen). 
During 5 d incubation the cells differentiated into iDCs. 
Some studies were also performed with mature human dendritic cells (mDCs). For maturation, iDCs 
were centrifuged at 1200 rpm for 5 min and the medium was replaced by 1 ml of human DC medium 
supplemented with 10 ng/ml rhIL-1, 10 ng/ml rhTNF- and 1 µg/ml PGE2. The cells were cultured 
for additional 2 d and maturation was confirmed by measuring the expression levels of CD80 and 
CD86 with flow cytometry according to chapter 3.2.9. 
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3.2.8.2.2 Preparation of human macrophages 
The isolation and generation of human macrophages from buffy coat were performed using a similar 
protocol as for human dendritic cells including density gradient centrifugation and a magnetic 
separation. 
Onto the top of 15 ml pre-warmed (37 °C) lymphocyte separation medium 25 ml of buffy coat diluted 
1:3 in pre-warmed PBS was layered. After centrifugation at 1600 rpm and RT for 30 min, the white 
interface was collected and macrophage wash medium was added up to a volume of 50 ml. The cells 
were centrifuged at 2200 rpm and RT for 8 min and the pellet was resuspended in 50 ml macrophage 
wash medium before centrifugation at 1600 rpm and RT for 8 min. Thrombocytes were removed by an 
additional washing of the pellet, centrifugation at 800 rpm and RT for 8 min and the supernatant was 
discarded. For lysis of red blood cells, 10 ml of cold 0.15 mol/l NH4Cl in water were added and 
incubated for 10 min to 15 min. Lysis was stopped by adjusting the volume to 50 ml with macrophage 
wash medium and the cells were centrifuged at 800 rpm and RT for 8 min. The cell number was 
determined and the magnetic separation of monocytes was performed as described in chapter 3.2.8.2.1. 
Around 4 107 to 5 107 PBMCs in 5 ml macrophage medium + 1 % (v/v) autologous plasma were 
seeded in a cell culture flask and incubated for 90 min at 37 °C and 5 % CO2. The non-adherent cells 
were removed by washing twice with 4 ml macrophage wash medium. 
The differentiation into M1 macrophages was carried out by addition of 5 ml macrophage medium 
supplemented with 10 ng/ml rhGM-CSF, whereas 4 ml macrophage medium supplemented 
with 30 ng/ml rhM-CSF (rh macrophage colony-stimulating factor) were used for the generation of M2 
macrophages. The cells were harvested after 5 d to 7 d incubation. 
 
 
3.2.8.2.3 Assessment of receptor expression by human DCs or macrophages 
To analyze surface receptor expression by DCs or macrophages, adherent human DCs or macrophages 
were generated as described in the chapters 3.2.8.2.1 and 3.2.8.2.2. The cells were harvested and 
directly stained for the co-stimulatory molecules CD80, CD86 or HLA-DR (human leukocyte 
antigen-DR; the homologue to mouse MHC class II) as well as for the receptors SR-AI/II, SR-BI, 
CD36 and the MR according to chapter 3.2.9.2. 
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3.2.8.2.4 Assessment of antigen uptake by human DCs or macrophages 
Antigen uptake by human iDCs as well as by human M1 or M2 macrophages was assessed according 
to Hilmenyuk et al.(100). Briefly, the cells were incubated with 0.5 µg/ml or 5 µg/ml of FITC-labelled 
OVA samples in the respective cell culture medium for 15 min, 60 min or 240 min, extensively 
washed, fixed with 1 % (w/v) PFA in PBS and afterwards analyzed with flow cytometry according to 
chapter 3.2.9. In vitro differentiation of PBMCs in DCs or macrophages resulted in highly homologous 
cell populations and therefore, it was not necessary to stain for specific cell surface markers. 
 
 
3.2.9 Flow cytometry 
Flow cytometry is a powerful tool for cell analysis and is used to study the properties of specific cell 
subsets.(99) The cells of interest are identified by staining of specific cell markers and molecules of 
interest on the cell surface with monoclonal antibodies labelled with a fluorescent dye.(99) Inside the 
flow cytometer, these marked cells are detected by passing through a laser beam and so-called 
fluorescence-activated cell sorter (FACS) are able to separate labelled from unlabelled cells.(99) 
For analysis, a very fine laminar stream of the cell suspension is created by forcing it with high 
pressure through a needle.(99) The encounter of a cell in the laminar stream with the laser beam causes 
light scattering as well as excitation of the dye leading to fluorescence.(99) The scattered light as well 
as the fluorescence is guided through a set of filters and splitters and is then detected by several 
photomultiplier tubes.(99) The detected signals become processed by a connected computer.(99) The 
forward and the sideward scattered light provide information about the cell size and the granularity of 
the cell, respectively.(99) The detected fluorescence resembles the expression levels of the stained cell 
surface molecules.(99) 
Flow cytometry was used in this thesis for many different purposes, like analysis of the maturation 
status of DCs, determination of antigen uptake by DCs and analysis of CD4
+
 T-cell proliferation. 
 
 
3.2.9.1 Blocking of Fc-receptor binding 
Receptors, which bind to the Fc-domain of antibodies, so-called Fc-receptors are present on the surface 
of many cells, like DCs and macrophages. False-positive signals by unspecific binding of the 
antibodies to Fc-receptors were excluded by blocking of Fc-receptors before staining of the respective 
surface molecules. 
All cells were washed twice with plenty FACS-buffer or PBS to remove residual cell culture medium, 
which can inhibit the staining. BMDCs used for direct staining according to chapter 3.2.9.2 were 
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incubated for 30 min at 4 °C with 50 µl anti-mouse CD16/CD32 diluted in FACS-buffer before 
staining. 
Blocking of human cells for detection of SR-BI was performed by incubation of the cells with 5 µl 
Human TruStain FcX™ (BioLegend; Fell) per 100 µl cell suspension for 5 min to 10 min at RT or 
with 20 µl of Human Fc Receptor Binding Inhibitor (eBioscience; Frankfurt a.M.) for 20 min on ice 
according to the manufacturer’s instructions. 
Afterwards, it was directly continued with the staining protocol. 
 
 
3.2.9.2 Direct staining of cell surface molecules 
Direct staining of cell surface molecules was performed for staining of the maturation markers CD40, 
CD80 and CD86, and of MHC class II molecules on BMDCs. Also staining of CD4 or CD8 on T-cells 
either for proliferation analysis with CFSE or for determination of T-cell purity was performed using 
the direct staining approach. For characterization of human DCs, direct staining of CD80, of CD86 and 
of HLA-DR was performed. Both human DCs and macrophages were stained for the receptors 
SR-AI/II, CD36, SR-BI and the MR. 
After blocking of the Fc-receptors, 50 µl of the appropriate antibody diluted in FACS-buffer were 
added to the blocking solution and the cells were incubated for additional 30 min at 4 °C in the dark. 
Plenty FACS-buffer was added and the cells were centrifuged at 1100 rpm and 4 °C for 5 min. Stained 
BMDCs were washed again with FACS-buffer and afterwards stained for CD11b and CD11c as 
described in chapter 3.2.9.4. 
All other cells were washed three times with plenty FACS-buffer. The cells were resuspended in a 
small volume of FACS-buffer and fixed by addition of 1 % (w/v) PFA in PBS. The cells were stored at 
4 °C in the dark until analysis. 
 
 
3.2.9.3 Indirect staining of cell surface receptors 
For staining of cell surface receptors where no specific fluorophore-antibody conjugate was available, 
an indirect staining by using a specific primary antibody and a dye-conjugated secondary antibody was 
mandatory. 
After blocking of the cells as described in chapter 3.2.9.1, the primary antibody was added to the cells 
and the sample was incubated for 30 min at 4 °C in the dark. The cells were washed twice with plenty 
PBS or FACS-buffer. The cells were resuspended in 100 µl of the respective blocking solution and the 
dye-conjugated secondary antibody was added. The cells were incubated for 30 min at 4 °C in the 
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dark. The staining reaction was quenched by addition of plenty PBS or FACS-buffer followed by 
washing once with FACS-buffer. 
BMDCs were afterwards stained for CD11b and CD11c as described in chapter 3.2.9.4 and human 
cells were extensively washed with FACS-buffer, fixed with 1 % (w/v) PFA in PBS and stored at 4 °C 
in the dark until analysis. 
 
 
3.2.9.4 Staining of BMDCs for CD11b and CD11c 
To distinguish the population of fully differentiated BMDCs from other cells, like remaining bone 
marrow cells, the cells were stained for CD11b and CD11c, which are specific markers for myeloid 
dendritic cells. 
The staining was performed by resuspending the washed cells in 50 µl of a cocktail containing 
anti-CD11c allophycocyanin (APC) mAb and anti-CD11b phycoerythrin (PE) mAb diluted in 
FACS-buffer and incubation for 30 min at 4 °C in the dark. The cells were washed once by addition of 
FACS-buffer. After centrifugation at 1200 rpm and 4 °C for 5 min, the cells were washed three times 
with FACS-buffer. The cells were resuspended in a small volume of FACS-buffer and fixed with 
1 % (w/v) PFA in PBS. The samples were stored in the fridge until analysis on the same day. 
 
 
3.2.10 Animal experimental methods 
The animal experiments were performed in agreement with the German legislation and guidelines of 
the Paul-Ehrlich-Institut. All mice were kept in the experimental animal facility at the Paul-Ehrlich-
Institut under specified pathogen free conditions. The mice received water and a special diet ad 
libitum. 
 
 
3.2.10.1 Sensitization of mice with i.p. injection 
Mice are usually not exposed to allergens that induce allergic reaction in humans. Therefore, the first 
allergen contact, which is termed sensitization, can be achieved by injection of the allergen together 
with a TH2-directing adjuvant into the mice. 
BALB/c mice (n = 6) were sensitized twice in a two week interval with 10 µg of either native OVA, 
Pyr-OVA or AGE-OVA in PBS together with 1 mg of aluminium hydroxide (ALUM) (Imject® 
ALUM; Thermo Scientific, Nidderau) as an adjuvant by intraperitoneal (i.p.) injection. As a control, 
mice (n = 3) were injected with 1 mg of ALUM suspended in PBS. 
 Materials and Methods 44 
3.2.10.2 Blood withdrawal from the tail 
Blood was taken from the tail vein of the mice one week after i.p. sensitization for the analysis of 
antigen-specific IgE, IgG1 and IgG2a antibodies in the sera. To stimulate the blood flow, the mice 
were warmed under an infrared lamp. The mice were fixated and the tail vein was cut with a 
razorblade. The blood was collected in a special tube for serum isolation (Sarstedt, Nümbrecht) and 
afterwards, the bleeding at the tail was stopped. The collected blood was clotted for 30 min at RT and 
the serum was separated by centrifugation at 10,000 xg for 3 min and stored at -20 °C until analysis. 
 
 
3.2.10.3 Induction of clinical symptoms 
The induction of clinical symptoms, also called challenge, in sensitized animals can be performed in 
different ways, e.g. by injection, feeding, supplementation to the drinking water, oral gavage or 
inhalation. In this food allergy model, which has been established by Burggraf et al., two weeks after 
the second sensitization mice were challenged by feeding a diet containing high amounts of OVA 
(EW-diet; ssniff Spezialdiäten GmbH, Soest) for one week.(101) During challenge, clinical symptoms, 
like loss of body weight and drop in body temperature, were monitored. After challenge, the mice were 
euthanized using gaseous CO2 to take blood as well as the mesenteric lymph nodes (MLN), which is 
the gut draining lymphoid organ. Proliferation of MLN-derived CD4
+
 T-cells was analyzed according 
to chapter 3.2.8.1.10 and the antibody levels in the sera were determined by ELISA as described in 
chapter 3.2.5.2. 
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4 Results and Discussion 
4.1 Identification of glycation structures to enhance the immunogenic and 
allergenic potency of ovalbumin using murine immune cells 
 
4.1.1 Introduction 
In this chapter, the immunogenic and allergenic properties of OVA modified with the representative 
glycation structures CEL, CML, MG-H1 or pyrraline were investigated. These glycation structures are 
present in industrially roasted peanuts and their composition in AGE-OVA is also known. To identify 
glycation structures contributing to the enhanced immunogenic properties of AGE-OVA, the 
CD4
+
 T-cell immunogenicity as well as the DC uptake of each modification was assessed. Finally, the 
potential allergenicity of AGE-OVA, of the glycation structure(s) with enhanced T-cell 
immunogenicity, and of native OVA were compared in a mouse model of intestinal allergy. 
 
 
4.1.2 Characterization of the modified OVAs with glycation structures 
To identify glycation structures enhancing the T-cell immunogenicity of a food allergen, OVA was 
modified with CEL, CML, pyrraline or MGO-derivatives of arginine, such as MG-H1 (figure 7A). 
Crude glycated OVA (AGE-OVA) was prepared by thermal incubation of OVA with glucose at 50 °C 
for six weeks, following a protocol used in a previous study.(71) The modification levels of the 
glycation structures were determined by GC-MS or RP-HPLC-DAD after acid hydrolysis and are 
shown in tables 11 and 12. AGE-OVA as well as OVA thermally incubated without glucose 
(inc. OVA) and the native protein served as controls. Chemical modification of OVA and analysis of 
glycation structures were performed by Dr. Anne Wellner under supervision of Prof. Thomas Henle 
(TU Dresden).  
 
Table 11: Levels of specific modification by glycation structures in OVA samples. 
sample CEL CML MG-H1 argpyrimidine pyrraline 3DG-H 
CE-OVA 363.3 - - - - - 
CM-OVA - 334.5 - - - - 
MGO-OVA - - 53.6 38.0 - - 
Pyr-OVA - - - - 236.4 116.2 
AGE-OVA - 28 - - 0.9 - 
data are given in µmol/g OVA determined with RP-HPLC 
- : not analyzed 
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Table 12: Levels of modification of lysine and arginine residues in OVA samples. 
sample specific modification total modification 
 Lys [%] Arg [%] Lys [%] Arg [%] 
CE-OVA 80.1 - 77.2 - 
CM-OVA 73.8 - 81.2 - 
MGO-OVA - 30.1 - 71.1 
Pyr-OVA 51.1 25.1 72.4 39.7 
AGE-OVA 41.3 - 69.8 - 
 
The modification of OVA with CEL or CML was very selective resulting in 77 % lysine modification 
with CEL in OVA modified with CEL (CE-OVA) or 81 % lysine modification with CML in OVA 
modified with CML (CM-OVA), respectively (table 12). Additionally, the presence of these glycation 
structures in CE-OVA, CM-OVA and AGE-OVA could be detected by ELISA using specific 
antibodies (figures 8A and 8B). The reactions of OVA with 3-DG to form pyrraline or with MGO to 
form MG-H1 are less selective. OVA modified with pyrraline (Pyr-OVA) contained 3-DG derived 
hydroimidazolones (3DG-H) (table 11 and figure 7B include all identified by-products) on 25 % of 
arginine residues as well as modification with unknown AGEs on 14 % of arginine residues and 11 % 
of lysine residues, respectively. In the reaction of OVA with MGO, arginine residues were modified 
with MG-H1 (53 µmol/g OVA) and argpyrimidine (38 µmol/g OVA), a common by-product of this 
reaction. The levels of MG-H1 and argpyrimidine in MGO-OVA modified 30.1 % of arginine 
residues. This result suggests that the majority, approximately 41 % of arginine residues, was modified 
with unknown AGE structures. Presence of GA-pyridine in OVA samples was detected by ELISA 
using a specific antibody. Pyr-OVA and MGO-OVA did not contain GA-pyridine modification 
(figures 8C and 8D). Detectable levels of GA-pyridine were only found in AGE-OVA. 
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Figure 7: Scheme of glycation structures. (A) Main products: 1: OVA with CEL (CE-OVA); 2: OVA with CML 
(CM-OVA), 3: OVA with MG-H1 (MGO-OVA), 4: OVA with pyrraline (Pyr-OVA). (B) By-products: 5: OVA with 
3-desoxyglucosulose induced hydroimidazolone (3DG-H) 6: OVA with argpyrimidine, 7: OVA with GA-pyridine. 
 
 
 
Figure 8: Detection of glycation structures in OVA by ELISA. (A) CEL, (B) CML and (C, D) GA-pyridine in OVA 
samples were detected by ELISA using antibodies specific for the indicated glycation structure. 
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To assess whether modification induces a molecular shift (e.g. aggregation) in the proteins, the OVA 
samples were subjected to SDS-PAGE under reducing conditions. For native OVA, shown in lane 1 in 
figure 9, one distinct band with an apparent molecular weight of around 45 kDa was visible. For 
inc. OVA, shown in lane 2, a second band of low intensity at a molecular weight of about 35 kDa was 
observed. This result suggests that the majority of OVA stays intact and only a small part degrades 
during thermal processing. CE-OVA, CM-OVA and MGO-OVA, shown in lane 3 to lane 5, seem to 
have a slightly higher molecular weight than native OVA due to modification. For Pyr-OVA, shown in 
lane 6, and AGE-OVA, shown in lane 7, broad smears around a molecular weight of 45 kDa, 100 kDa 
to 130 kDa and above are visible. The smear bands of AGE-OVA suggest that OVA could be modified 
with many different glycation structures. More than 100 kDa bands of Pyr-OVA and AGE-OVA 
indicate that aggregates formed by cross-linking AGEs are present in these samples. 
 
 
Figure 9: Analysis of the modified OVAs with SDS-PAGE. OVA samples (5 µg/lane) were loaded on a reducing 7.5 % 
TRIS-glycine gel and stained with Coomassie Brilliant Blue after electrophoresis. Lane M: molecular weight marker, 
lane 1: native OVA, lane 2: inc. OVA, lane 3: CE-OVA, lane 4: CM-OVA, lane 5: MGO-OVA, lane 6: Pyr-OVA, 
lane 7: AGE-OVA. 
 
Next, the secondary structure of all OVA samples was analyzed with CD-spectroscopy. The 
CD-spectra of all forms of OVA look similar (figure 10). The shape of the curves with two minima at 
approximately 221 nm and 210 nm and a maximum at approximately 190 nm indicate that the 
structure is composed mainly of -helices, as it is known for the native form of OVA.(17) These 
results suggest that there seem to be only minor changes in the secondary structure elements of OVA 
due to modification. 
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Figure 10: CD-spectra of (A) native OVA, inc. OVA and AGE-OVA as well as of (B) all modified OVAs. 
 
 
4.1.3 Characterization of AGE-BSA 
As a control for some experiments, crude glycated BSA (AGE-BSA) was prepared under the same 
conditions as used for AGE-OVA, i.e. by incubation of BSA with glucose at 50 °C for six weeks. The 
presence of the glycation structures CEL, CML and GA-pyridine was assessed by ELISA. 
As seen in AGE-OVA, CEL, CML and GA-pyridine were detected in AGE-BSA (figure 11). 
SDS-PAGE analysis showed the distinct band of native BSA or inc. BSA in lane 1 and lane 2 in 
figure 12. The band of AGE-BSA in lane 3 was a broad smear. The smear was also observed for 
AGE-OVA. Taken together, the results suggest that AGE-BSA could have a similar glycation profile 
as detected in AGE-OVA and is a suitable control for AGE-OVA. 
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Figure 11: Detection of glycation structures in the BSA samples by ELISA. (A) CEL, (B) CML and (C) GA-pyridine in 
inc. BSA and AGE-BSA were detected by ELISA using antibodies specific for the indicated glycation structure. 
 
 
Figure 12: Analysis of AGE-BSA by SDS-PAGE.  BSA samples (5 µg/lane) were loaded on a 10 % reducing 
TRIS-glycine gel and stained with Coomassie Brilliant Blue after electrophoresis. Lane M: molecular weight marker, 
lane 1: native BSA, lane 2: inc. BSA, lane 3: AGE-BSA. 
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4.1.4 Assessment of the T-cell immunogenicity of the modified OVAs with glycation structures 
in vitro  
Next, the CD4
+
 and the CD8
+
 T-cell immunogenicity of OVA was assessed. The CD4
+
 T-cell 
immunogenicity was assessed, because CD4
+
 T-cells play a crucial role to induce food allergies. The 
CD8
+
 T-cell immunogenicity was also assessed as it is known that OVA activates not only 
CD4
+
 T-cells, but also CD8
+
 T-cells due to its natural mannose residues. Several studies have shown 
that OVA binds to the mannose receptor (MR) expressed on the cell surface of DCs, which leads to 
cross-presentation of OVA to CD8
+
 T-cells. (59, 64) 
T-cell immunogenicity was assessed by measuring IL-2 production and proliferation of T-cells upon 
stimulation with OVA samples in a co-culture system with bone marrow-derived dendritic cells 
(BMDCs). 
 
 
4.1.4.1 IL-2 production by OVA-specific CD4+ T-cells stimulated by the OVAs modified 
with glycation structures 
The analysis of IL-2 production, also an indicator for T-cell activation, by OVA-specific CD4
+
 T-cells 
stimulated with the OVAs modified with glycation structures was performed using an in vitro 
co-culture system of OVA-specific CD4
+
 T-cells with BMDCs. BMDCs have been generally used as a 
model for antigen presenting cells (APCs). OVA-specific CD4
+
 T-cells were isolated from OT-II mice 
on a C57BL/6 background, or from DO11.10 mice on a BALB/c background. In homozygous OT-II 
mice and DO11.10 mice, around 80 % to 85 % of CD4
+
 T-cells express monoclonal TCR recognizing 
the amino acid region 323 to 339 in OVA.(102) This region corresponds to the sequence 
ISQAVHAAHAEINEAGR in the one letter notation for amino acids. CD4
+
 T-cells from OT-II mice 
are specific for the MHC class II haplotype I-A
b
, whereas those from DO11.10 mice are specific for 
the haplotype I-A
d
. 
In this thesis, both mouse strains are compared, because C57BL/6 mice tend to develop TH1 and TH17 
immune responses in contrast to BALB/c mice, which tend to develop TH2 responses. Another reason 
for the use of OT-II mice is that many genetically modified mouse strains are on a C57BL/6 
background. 
A co-culture system of OVA-specific CD4
+
 T-cells and syngeneic BMDCs (i.e. cells generated from 
mice on the same genetic background) was used to assess IL-2 production by T-cells. The cells were 
stimulated with 2 µg/ml or 20 µg/ml of either form of OVA. Stimulation with OVA leads to activation 
of the CD4
+
 T-cells, which subsequently produce the cytokine IL-2. The concentration of IL-2 in the 
cell culture supernatants was measured by ELISA. 
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AGE-OVA induced production of higher amounts of IL-2 by OT-II-derived CD4
+
 T-cells (OT-II cells) 
compared to native OVA (figure 13A). Of the modified OVAs, only Pyr-OVA induced significantly 
higher levels of IL-2 production by OT-II cells compared to native OVA. CE-OVA, CM-OVA or 
MGO-OVA induced comparable IL-2 production by OT-II cells as the one by native OVA and 
inc. OVA. A similar result was observed when BALB/c-derived BMDCs and DO11.10-derived 
CD4
+
 T-cells (DO11.10 cells) were used for the co-culture system (figure 13B). Pyr-OVA and 
AGE-OVA induced production of enhanced amounts of IL-2 by DO11.10 cells compared to native 
OVA. CE-OVA, CM-OVA and MGO-OVA slightly enhanced IL-2 production, but it was not 
remarkable, when the cells were stimulated with the lower concentration of 2.0 µg/ml. These results 
suggest that of the modifed OVA samples assessed in this experiment, Pyr-OVA induces significantly 
higher CD4
+
 T-cell activation. 
 
 
Figure 13: IL-2 production by OT-II- or DO11.10-derived CD4
+
 T-cells upon stimulation with OVA samples. 
CD4
+
 T-cells were isolated from (A) OT-II mice or (B) DO11.10 mice and co-cultured with syngeneic BMDCs in the 
presence of 2 µg/ml or 20 µg/ml of OVA samples. After 24 h of co-culture, the concentration of IL-2 in the cell culture 
supernatants was determined by ELISA. * p < 0.05, ** p < 0.01, *** p < 0.001 (n.d.: not detectable; below detection limit 
of 0.05 pg/ml). 
 
As mentioned above, Pyr-OVA contained not only pyrraline but also 3DG-H and other unknown 
glycation structures (see Pyr-OVA 3 in table 13). Protein aggregation was also induced during 
formation of Pyr-OVA by incubation of OVA with 3-DG (figures 9 and 14). To examine whether the 
enhanced CD4
+
 T-cell activation by Pyr-OVA was due to pyrraline, OVA was incubated with 3-DG at 
70 °C for shorter duration to reduce the levels of unspecific modification. Pyr-OVA 1 and Pyr-OVA 2 
prepared by 10 min and 30 min incubation, respectively, reduced the levels of unspecific by-products 
(table 13) and protein aggregation (figure 14) compared to Pyr-OVA 3 prepared by 4 h incubation, 
which has been used in the former experiments. 
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Table 13: Levels of modification in Pyr-OVA samples. 
sample pyrraline 3DG-H specific modification total modification 
 [µmol/g protein] Lys [%] Arg [%] Lys [%] Arg [%] 
Pyr-OVA 1 50.7 7.8 10.9 1.7 12.6 0.6 
Pyr-OVA 2 143.5 33.8 31.0 7.3 36.4 11.8 
Pyr-OVA 3 236.4 116.2 51.1 25.1 72.4 39.7 
modification levels of Pyr-OVA samples with Pyr and 3-DG in µmol/g OVA determined with RP-HPLC as well as 
percentage of total lysine and arginine modification assessed with amino acid analysis. 
 
 
Figure 14: Aggregation of Pyr-OVA samples. Pyr-OVA samples (5 - 10 µg/lane) were loaded on a 4 % to 20 % 
acrylamide gradient gel for SDS-PAGE under non-reducing conditions and (A) stained with Coomassie Brilliant Blue 
followed by (B) densitometric analysis. M: molecular weight marker, 1: native OVA, 2: OVA incubated w/o 3-DG, 
3: Pyr-OVA 1, 4: Pyr-OVA 2, 5: Pyr-OVA 3. 
 
Pyr-OVA 1 and Pyr-OVA 2 still induced higher IL-2 production by OT-II cells and DO11.10 cells 
compared to native OVA, as can be seen in figure 15. Enhanced CD4
+
 T-cell activation by Pyr-OVAs 
depended on pyrraline modification levels. OVA incubated at 70 °C without 3-DG, a control for 
Pyr-OVA, induced only basal levels of CD4
+
 T-cell activation as did native OVA (data not shown). 
Figure 15 shows that Pyr-OVA 1 induced production of lower levels of IL-2 compared to Pyr-OVA 3. 
In addition, the results indicate that Pyr-, but not 3DG-H-modification, causes the enhanced T-cell 
activation, because levels of 3DG-H in Pyr-OVA 1 are nearly at the detection level and significantly 
lower compared to Pyr-OVA 3. Thus, these results suggest that pyrraline could contribute to the 
enhanced CD4
+
 T-cell activation of Pyr-OVA. 
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Figure 15: IL-2 production by OT-II- or DO11.10-derived CD4
+
 T-cells upon stimulation with Pyr-OVAs. 
CD4
+
 T-cells were isolated from (A) OT-II or (B) DO11.10 mice and co-cultured with syngeneic BMDCs in the presence 
of 2 µg/ml or 20 µg/ml of OVA samples. After 24 h of co-culture, the concentration of IL-2 in the cell culture supernatants 
was determined by ELISA. (n.d.: not detectable; below detection limit of 0.05 pg/ml) 
 
 
4.1.4.2 Proliferation of OVA-specific CD4+ T-cells stimulated by the OVAs modified with 
glycation structures 
To further assess CD4
+
 T-cell activation by OVA samples, T-cell proliferation was analyzed. 
Stimulation of T-cells with OVA induces T-cell activation, which is characterized by T-cell 
proliferation as well as cytokine production by T-cells and thus, T-cell proliferation can be used as a 
marker for T-cell activation. 
To measure the proliferation of OVA-specific CD4
+
 T-cells, T-cells were stained with CFSE, a 
chemical with green fluorescence, prior to their culture with BMDCs in the presence of 2 µg/ml of 
either form of OVA. Cell proliferation was analyzed by measuring CFSE intensity of the CD4
+
 T-cells 
using flow cytometry. 
Pyr-OVA 3, which has been used in all following experiments and is referred to as Pyr-OVA, and 
AGE-OVA induced higher proliferation of OT-II cells compared to native OVA (figure 16). CE-OVA 
induced a slightly higher T-cell proliferation compared to native OVA. All other forms of OVA, i.e. 
inc. OVA, CM-OVA and MGO-OVA, induced similar levels of T-cell proliferation as did native 
OVA. These results suggest that modification of OVA with pyrraline induces higher CD4
+
 T-cell 
activation. 
Like in measurements of IL-2 production, DO11.10 cells showed similar proliferation against the 
OVA samples as did OT-II cells (figure 17). Pyr-OVA and AGE-OVA induced higher proliferation of 
DO11.10 cells than other OVAs. Here, a slightly enhanced proliferation by CE-OVA was also 
observed. 
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Enhanced IL-2 production and proliferation of both OT-II and DO11.10 cells by Pyr-OVA suggest that 
this modified OVA has a considerably higher CD4
+
 T-cell immunogenicity than native OVA and the 
other OVAs modified with glycation structure. 
 
 
Figure 16: Proliferation of OT-II-derived CD4
+
 T-cells upon stimulation with OVA samples. CD4
+
 T-cells isolated 
from OT-II mice were stained with CFSE and co-cultured with syngeneic BMDCs in the presence of 2 µg/ml of OVA 
samples. After 96 h of co-culture, CFSE intensity of CD4
+
 T-cells was measured with flow cytometry. 
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Figure 17: Proliferation of DO11.10-derived CD4
+
 T-cells upon stimulation with OVA samples. CD4
+
 T-cells isolated 
from DO11.10 mice were stained with CFSE and co-cultured with syngeneic BMDCs in the presence of 2 µg/ml of OVA 
samples. After 96 h of co-culture, CFSE intensity of CD4
+
 T-cells was measured with flow cytometry. 
 
 
4.1.4.3 TH1, TH2 and TH17 cytokine production by OVA-specific CD4
+
 T-cells stimulated by 
the OVAs modified with glycation structures 
Naive CD4
+
 T-cells differentiate into three different subsets of effector cells, i.e. TH1, TH2 and TH17 
cells. It has been an important question whether AGEs influence the differentiation of T-cells. To 
investigate the influence of AGEs on T-cell differentiation, cytokine production by OT-II cells and 
DO11.10 cells upon stimulation with OVA samples was measured. OVA-specific CD4
+
 T-cells were 
co-cultured with BMDCs upon stimulation with either 2 µg/ml or 20 µg/ml of modified OVAs for 
72 h. The concentrations of the TH1-related cytokine IFN-γ, the TH2-related cytokine IL-4 and the 
TH17-related cytokine IL-17A in the cell culture supernatants were determined by ELISA. 
Results of IFN-γ and IL-17A production by OT-II cells are shown in figure 18. IL-4 was not detected 
in the cell culture supernatants of OT-II cells due to the C57BL/6 background of the mice. Pyr-OVA 
induced the highest levels of IFN-γ and IL-17A production by OT-II cells. AGE-OVA induced higher 
levels of IFN-γ and IL-17A production at a concentration of 2 µg/ml, but not at 20 µg/ml. A possible 
explanation might be that the viability of the CD4
+
 T-cells might be weakened after 72 h of co-culture 
due to overstimulation of the T-cells by AGE-OVA or toxicity of this crude glycation product at higher 
concentrations. The putative toxicity of AGE-OVA may also be an explanation for the strong levels of 
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IL-2 induced by AGE-OVA compared to native OVA and the lower levels of IFN-γ and IL-17A 
induced by AGE-OVA compared to native OVA, because levels of IL-2 were measured after 24 h of 
cell culture compared to the levels of IFN-γ and IL-17A, which were measured after 72 h of cell 
culture. The other modified OVAs tended to induce slightly higher levels of IFN-γ and IL-17A by 
OT-II cells compared to native OVA. 
 
 
Figure 18: TH1 and TH17 cytokine production by OT-II-derived CD4
+
 T-cells upon stimulation with OVA samples. 
CD4
+
 T-cells were isolated from OT-II mice and co-cultured with syngeneic BMDCs in the presence of 2 µg/ml or 
20 µg/ml of OVA samples. After 72 h of co-culture, the concentrations of (A) IFN-γ or (B) IL-17A in the cell culture 
supernatants were determined by ELISA. * p < 0.05, ** p < 0.01, *** p < 0.001 (n.d.: not detectable; below detection limit 
of 0.01 pg/ml). 
 
DO11.10 cells produced detectable levels of IL-4 and IL-17A, but not of IFN-γ, in the co-culture 
system with BMDCs. Of the OVA samples, Pyr-OVA and AGE-OVA induced higher levels of IL-4 
production by DO11.10 cells at 2 µg/ml, the low concentration used, compared to native OVA and the 
other modified OVAs (figure 19A). However, IL-4 production by DO11.10 cells was reduced when 
the cells were stimulated with 20 µg/ml of Pyr-OVA or AGE-OVA. In contrast, native OVA and the 
other modified OVAs induced higher IL-4 production by DO11.10 cells at a concentration of 
20 µg/ml. DO11.10 cells also induced detectable levels of IL-17A, which are shown in figure 19B. 
IL-17A production by DO11.10 cells was remarkably enhanced when the cells were stimulated with 
20 µg/ml of Pyr-OVA compared to the other OVA samples including native OVA. These results 
suggest first, that the threshold to induce IL-4 production could be lower than that to induce IL-17A 
production by DO11.10 cells, second, that the reduced IL-4 production of DO11.10 cells by 20 µg/ml 
of Pyr-OVA could be an over-dosation of this material, and third, that Pyr-OVA is capable of inducing 
higher T-cell stimulation than the other modified OVAs and native OVA. 
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Figure 19: TH2 and TH17 cytokine production by DO11.10-derived CD4
+
 T-cells upon stimulation with OVA 
samples. CD4
+
 T-cells were isolated from DO11.10 mice and co-cultured with syngeneic BMDCs in the presence of 
2 µg/ml or 20 µg/ml of OVA samples. After 72 h of co-culture the concentrations of (A) IL-4 or (B) IL-17A in the cell 
culture supernatants were determined by ELISA. (n.d.: not detectable; below detection limit of 0.01 pg/ml) 
 
Taken together, Pyr-OVA enhanced both the production of the TH1-related cytokine IFN-γ and the 
TH2-related cytokine IL-4 by OT-II cells and DO11.10 cells, respectively. Furthermore, Pyr-OVA 
enhanced production of IL-17A, a TH17-related cytokine, by both cell types. These results suggest that 
Pyr-OVA does not bias the differentiation of CD4
+
 T-cells into a specific TH subset. 
 
 
4.1.4.4 IL-2 and IFN-γ production by OVA-specific CD8+ T-cells stimulated by the OVAs 
modified with glycation structures 
Next, the CD8
+
 T-cell immunogenicity of the OVA samples was assessed. For the assessment, a 
co-culture system of OT-I-derived CD8
+
 T-cells (OT-I cells) with syngeneic BMDCs was used 
following a protocol established by Burgdorf et al.(59) The genetically modified mouse strain OT-I is 
on a C57BL/6 background and expresses an OVA-specific TCR. This TCR recognizes complexes of 
the MHC class I molecule K
b
 with an OVA peptide containing the amino acid region 257 to 264 
(SIINFEKL). In this assay, BMDCs were stimulated with LPS before co-culture, because this 
enhances cross-presentation of exogenous antigens by MHC class I molecules.(103) As a marker for 
CD8
+
 T-cell activation, the concentration of IL-2 in the cell culture supernatants was determined by 
ELISA. 
Figure 20 shows that AGE-OVA and native OVA induced similar levels of IL-2 production by OT-I 
cells. These results indicate that AGE-OVA was not capable of enhancing CD8
+
 T-cell activation. 
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Figure 20: IL-2 production by OT-I-derived CD8
+
 T-cells upon stimulation with OVA samples. CD8
+
 T-cells were 
isolated from OT-I mice. Syngeneic BMDCs were treated with 10 µg/ml LPS for 2 h, incubated with 20 µg/ml or 
200 µg/ml of OVA samples for 3 h and washed. OT-I cells and OVA sample-primed BMDCs were cultured for 20 h. The 
concentration of IL-2 in the cell culture supernatants was then determined by ELISA. (n.d.: not detectable; below detection 
limit of 0.01 pg/ml) 
 
CD8
+
 T-cell activation leads to the initiation of the natural cytotoxic effector function and the release 
of cytotoxic mediators. As a part of this response, the cells produce the cytokine IFN-γ. Thus, the 
functionality of the CD8
+
 T-cells can be checked by measuring the IFN-γ concentration in the cell 
culture supernatants by ELISA. To verify the CD8
+
 T-cell activation by OVA samples, the 
concentration of IFN-γ in the cell culture supernatants after 72 h of co-culture was determined by 
ELISA. 
As expected, levels of IFN-γ production correlate well with those of IL-2 production by OT-I cells 
stimulated with OVA samples (figures 20 and 21). No enhanced production of IFN-γ was observed by 
OT-I cells stimulated with neither AGE-OVA nor Pyr-OVA. These results suggest that modification of 
OVA with pyrraline or other glycation structures did not influence the CD8
+
 T-cell immunogenicity of 
OVA. 
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Figure 21: IFN-γ production by OT-I-derived CD8+ T-cells upon stimulation with OVA samples. CD8+ T-cells were 
isolated from OT-I mice. Syngeneic BMDCs were treated with 10 µg/ml LPS for 2 h, incubated with 20 µg/ml or 
200 µg/ml of OVA samples for 3 h and washed. OT-I cells and OVA sample-primed BMDCs were cultured for 72 h. The 
concentration of IFN-γ in the cell culture supernatants was determined by ELISA. 
 
 
4.1.5 Interaction of modified OVAs with BMDCs in vitro  
 
4.1.5.1 Non-effect of the OVAs modified with glycation structures on BMDC maturation 
Antigen uptake and maturation of DCs is a prerequisite for efficient activation of CD4
+
 or 
CD8
+
 T-cells. Several studies have indicated that some AGEs have the potential to influence DC 
maturation.(104, 105) Hence, it was assessed whether the OVAs modified with glycation structures 
induce BMDC maturation. 
BMDCs were stimulated with 50 µg/ml of OVA sample or 1 µg/ml of LPS, a pyrogen known to 
induce DC maturation, for 18 h. Expression levels of the co-stimulatory molecules CD40, CD80 and 
CD86 as well as of MHC class II molecules on the cell surface of BMDCs were measured with flow 
cytometry. Additionally, the concentration of IL-6 in the cell culture supernatants was determined by 
ELISA. 
The expression levels of the co-stimulatory molecules on BMDCs stimulated with either OVA sample 
were comparable to those of non-stimulated cells (figure 22A). In contrast, incubation of BMDCs with 
LPS resulted in increased levels of CD40, CD80, CD86 and MHC class II molecules on the cell 
surface (figure 22B), showing that the BMDCs were functional. Levels of IL-6 induced by Pyr-OVA 
and AGE-OVA (figure 23) as well as by all other modified OVAs (data not shown) were comparable 
to those of native OVA and non-stimulated cells. Incubation of BMDCs in the presence of LPS 
induced production of higher levels of IL-6 compared to non-stimulated cells. The results suggest that 
maturation of BMDCs is not induced by the OVAs modified with glycation structures. 
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Figure 22: Co-stimulatory molecule and MHC class II expression by BMDCs upon stimulation with OVA samples. 
C57BL/6-derived BMDCs were incubated with (A) 50 µg/ml of OVA sample or (B) 1 µg/ml of LPS for 18 h (blue) or with 
medium only (red). The cells were then stained using anti-CD40, CD80, CD86 or MHC class II mAb for maturation 
markers, as well as anti-CD11b and CD11c mAbs for DC surface markers. The expression levels of the maturation markers 
on the cell surface of CD11b
+
CD11c
+
 cells were analyzed with flow cytometry. Grey areas represent unstained BMDCs 
and black lines indicate BMDCs incubated with the respective isotype control antibody. 
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Figure 23: IL-6 production by BMDCs upon stimulation with OVA samples. C57BL/6-derived BMDCs were 
incubated with 5 µg/ml or 50 µg/ml of native OVA, Pyr-OVA, AGE-OVA or 1 µg/ml of LPS for 18 h. The concentration 
of IL-6 in the cell culture supernatants was determined by ELISA. 
 
 
4.1.5.2 Uptake of the OVAs modified with glycation structures by BMDCs 
A previous study showed that AGE-OVA was highly taken up by BMDCs compared to native OVA 
and inc. OVA.(71) Therefore, the uptake of the modified OVAs was assessed, to see if the specific 
modification enhances the allergen uptake by BMDCs. For this assessment, the OVA samples were 
labelled with FITC, a green fluorescent dye, at comparable FITC/protein-ratios. For the uptake assay, 
also native OVA, inc. OVA and AGE-OVA as well as BSA samples labelled with FITC were used for 
control experiments. Typical data of FITC/protein-ratios of the OVA samples and the BSA samples 
are shown in tables 14 and 15, respectively. BMDCs were incubated with either 0.5 µg/ml or 5 µg/ml 
of FITC-labelled sample for 15 min. The FITC intensity of the CD11b
+
CD11c
+
 population of the cells 
was then assessed with flow cytometry. 
 
Table 14: Calculated molar FITC/protein-ratios of FITC-labelled OVA samples. 
sample molar FITC/protein 
native OVA 0.46 
inc. OVA 0.42 
AGE-OVA 0.42 
CM-OVA 0.58 
CE-OVA 0.43 
MGO-OVA 0.63 
Pyr-OVA 0.36 
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Table 15: Calculated molar FITC/protein-ratios of FITC-labelled BSA samples. 
sample molar FITC/protein 
native BSA 1.55 
inc. BSA 1.38 
AGE-BSA 1.35 
 
 
4.1.5.2.1 Influence of the glycation structure on the antigen uptake by BMDCs 
The observed stronger signals for BMDCs incubated in the presence of AGE-OVA compared to native 
OVA indicate that AGE-OVA is taken up to a stronger extent by BMDCs than native OVA (figures 24 
and 25). Also for Pyr-OVA an enhanced antigen uptake by BMDCs was observed. The high uptake of 
Pyr-OVA and AGE-OVA is visible at both analyzed concentrations. At a concentration of 5 µg/ml a 
slightly enhanced uptake of CE-OVA and CM-OVA can be seen, which is absent at the antigen dose 
of 0.5 µg/ml. The uptake of MGO-OVA is comparable to that of native OVA. These results indicate 
that Pyr-OVA as well as AGE-OVA, but not the other OVAs modified with glycation structures or 
native OVA, are highly taken up by BMDCs. 
 
 
Figure 24: Uptake of 5 µg/ml OVA samples by BMDCs. C57BL/6-derived BMDCs were incubated with 5 µg/ml of 
FITC-labelled OVA samples for 15 min. The uptake of the OVA samples by CD11b
+
CD11c
+
 BMDCs was measured with 
flow cytometry. Grey areas represent BMDCs cultured without antigen. 
 Results and Discussion 64 
 
Figure 25: Uptake of 0.5 µg/ml OVA samples by BMDCs. C57BL/6-derived BMDCs were incubated with 0.5 µg/ml of 
FITC-labelled OVA samples for 15 min. The uptake of the OVA samples by CD11b
+
CD11c
+
 BMDCs was measured with 
flow cytometry. Grey areas represent BMDCs cultured without antigen. 
 
 
4.1.5.2.2 Involvement of SR-AI/II in the uptake of Pyr-OVA by BMDCs 
The role of SR-AI/II (CD204) in the uptake of the modified OVAs by BMDCs was investigated by 
comparing the uptake of the modified OVAs with glycation structures by BMDCs derived from 
B6.Cg-Msr1 (SR-A
-/-
) mice, which are deficient for SR-AI/II and on a C57BL/6 background, and wt 
mice. For this purpose, either wt or SR-A
-/-
 BMDCs were incubated with 0.5 µg/ml or 5 µg/ml of OVA 
sample for 15 min. FITC intensity of CD11b
+
CD11c
+
 cells, namely the myeloid dendritic cell 
population in BMDCs, was then analyzed with flow cytometry. 
As shown in the figures 26 and 27, native OVA was taken up to a comparable extent by wt and SR-A
-/-
 
BMDCs. In contrast, uptake of Pyr-OVA and AGE-OVA was reduced in SR-A
-/-
 cells, although slight 
levels of uptake of Pyr-OVA and AGE-OVA by SR-A
-/-
 BMDCs were observed. Uptake levels of the 
other OVA samples modified with glycation structures were comparable in wt and SR-A
-/-
 BMDCs. 
These results suggest that SR-AI/II mediates the uptake of Pyr-OVA and AGE-OVA by BMDCs. The 
residual uptake of AGE-OVA and Pyr-OVA by SR-A
-/-
 cells indicate that other receptor(s) are 
involved in the uptake of Pyr-OVA and AGE-OVA by BMDCs. 
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Figure 26: Uptake of 5 µg/ml of OVA samples by SR-A
-/-
 BMDCs. Wt BMDCs (red) or SR-A-/- BMDCs (blue) were 
incubated with 5 µg/ml of FITC-labelled OVA samples for 15 min. FITC intensity of CD11b
+
CD11c
+
 BMDCs was 
measured using flow cytometry. Grey areas and the black curves represent BMDCs cultured without antigen. 
 
 
Figure 27: Uptake of 0.5 µg/ml of OVA samples by SR-A
-/-
 BMDCs. Wt BMDCs (red) or SR-A
-/-
 BMDCs (blue) were 
incubated with 0.5 µg/ml of FITC-labelled OVA samples for 15 min. FITC intensity of CD11b
+
CD11c
+
 BMDCs was 
measured using flow cytometry. Grey areas and the black curves represent BMDCs cultured without antigen. 
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4.1.5.2.3 Non-involvement of galectin-3 in the uptake of Pyr-OVA by BMDCs 
Next, an involvement of galectin-3 in the uptake of Pyr-OVA and AGE-OVA by BMDCs was 
assessed by pre-treatment of SR-A
-/-
 BMDCs with 150 mmol/l of lactose, a galectin-3 inhibitor, for 
30 min before incubation with the FITC-labelled OVA samples. Lactose binds to galectin-3 with high 
affinity and therefore, blocks binding of all other ligands to galectin-3.(106) Here, it was focused on 
assessing the uptake of Pyr-OVA and AGE-OVA in comparison to native OVA to analyze which other 
receptor is involved in the residual uptake of Pyr-OVA and AGE-OVA by SR-A
-/-
 BMDCs. 
As shown in figure 28, pre-treatment of wt and SR-A
-/-
 BMDCs did not inhibit the uptake of the tested 
OVA samples. Similar OVA uptake was detected in pre-treated and non-treated BMDCs with lactose. 
These results suggest that galectin-3 is not involved in the uptake of Pyr-OVA and AGE-OVA. 
 
 
Figure 28: Uptake of native OVA, Pyr-OVA and AGE-OVA by BMDCs after inhibition of galectin-3 with lactose. 
Wt or SR-A
-/-
 BMDCs were treated with 150 mmol/l of lactose 30 min prior to incubation with 5 µg/ml of FITC-labelled 
native OVA, Pyr-OVA or AGE-OVA for 15 min. FITC intensity of CD11b
+
CD11c
+
 cells was analyzed with flow 
cytometry. Grey areas represent BMDCs cultured without antigen. 
 
 
4.1.5.2.4 Non-involvement of SR-BI in the uptake of Pyr-OVA and AGE-OVA by BMDCs 
An involvement of SR-BI in the uptake of the OVA samples was assessed using phosphatidylserine 
(PdS), a SR-BI ligand, as well as the SR-BI inhibitor BLT-1. Nieland et al. showed that both 1 µmol/l 
or 10 µmol/l of BLT-1 efficiently block the uptake of high density lipoprotein, a natural SR-BI 
ligand.(107) He et al. showed that 100 µg/ml of PdS efficiently inhibit binding of other ligands to 
SR-BI.(108) Hence, SR-A
-/-
 BMDCs were incubated with 1 µmol/l or 10 µmol/l of BLT-1 or 
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100 µg/ml of PdS for 30 min before the addition of 5 µg/ml of FITC-labelled OVA samples. As 
control, SR-A
-/-
 BMDCs were incubated with 0.2 % DMSO in DC medium, because BLT-1 was 
solved in DMSO according to the manufacturer’s instructions. 
The uptake of Pyr-OVA and AGE-OVA after pre-treatment of SR-A
-/-
 BMDCs with BLT-1 was 
comparable to the uptake by non-treated cells (figure 29). Pre-treatment of SR-A
-/-
 BMDCs with PdS 
also did not reduce the uptake of OVA samples (figure 30). These results suggest that SR-BI is not 
involved in the uptake of Pyr-OVA and AGE-OVA. 
 
 
Figure 29: Uptake of OVA samples by BMDCs after inhibition of SR-BI with BLT-1. SR-A
-/-
 BMDCs were incubated 
with or without 1 µmol/l or 10 µmol/l of BLT-1 in 0.2 % DMSO for 30 min and then incubated with 5 µg/ml of 
FITC-labelled native OVA, Pyr-OVA or AGE-OVA for 15 min. FITC intensity of CD11b
+
CD11c
+
 cells was analyzed with 
flow cytometry. Grey areas represent BMDCs cultured without antigen. 
 
 
Figure 30: Uptake of OVA samples by BMDCs after inhibition of SR-BI with PdS. SR-A
-/-
 BMDCs were incubated 
with or without 100 µg/ml of phosphatidylserine (PdS) for 30 min and then incubated with 5 µg/ml of FITC-labelled native 
OVA, Pyr-OVA or AGE-OVA for 15 min. FITC intensity of CD11b
+
CD11c
+
 cells was analyzed with flow cytometry.  
Grey areas represent BMDCs cultured without antigen. 
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4.1.5.2.5 Non-involvement of CD36 in the uptake of Pyr-OVA and AGE-OVA by BMDCs 
CD36, another member of the SR-B family, was shown to bind AGEs.(51) Therefore, CD36 was an 
interesting target for this study. A specific inhibitor for CD36 had not been available. Thus, 
involvement of CD36 in the uptake of Pyr-OVA or AGE-OVA by BMDCs was assessed by 
neutralizing antibodies to block interaction of CD36 with ligands. To exclude an involvement of 
SR-AI/II in the uptake of OVA samples in this assessment, SR-A
-/-
 BMDCs were used. The cells were 
pre-treated with 2 µg/ml of anti-CD36 antibodies for 30 min and then incubated with 5 µg/ml of 
FITC-labelled OVA sample for 15 min. 
Pre-treatment with antibodies against CD36 did not reduce the uptake of native OVA, Pyr-OVA and 
AGE-OVA by SR-A
-/-
 BMDCs, as can be seen in figure 31A. Binding of these antibodies against 
CD36 expressed on the cell surface of BMDCs was confirmed with flow cytometry, as shown in 
figure 31B. These results suggest that CD36 does not play a role in the uptake of Pyr-OVA and 
AGE-OVA. 
 
 
Figure 31: Uptake of OVA samples after blocking of CD36 and binding of anti-CD36 antibodies to BMDCs. SR-A
-/-
 
BMDCs were incubated with 2 µg/ml of anti-mouse CD36 IgA antibodies for 30 min and (A) then incubated with 5 µg/ml 
of FITC-labelled native OVA, Pyr-OVA or AGE-OVA for 15 min or (B) incubated with of FITC-labelled goat anti-mouse 
IgA antibody. FITC intensity of CD11b
+
CD11c
+
 BMDCs was analyzed with flow cytometry. 
 
 
4.1.5.2.6 Involvement of the mannose receptor in the uptake of Pyr-OVA by BMDCs 
The uptake of the modified OVAs by the MR needed to be considered, because native OVA is a 
glycosylated protein and possess natural mannose residues binding to the MR.(19, 59) Indeed, 
mannan, a mannose-containing polysaccharide, has been utilized as an inhibitor for the MR. To 
investigate an involvement of the MR in the uptake of Pyr-OVA and AGE-OVA, wt or SR-A
-/-
 
BMDCs were treated with 3 mg/ml of mannan before incubation with 5 µg/ml of FITC-labelled OVA 
samples. BSA does not contain natural carbohydrate residues and therefore, the uptake of native BSA, 
inc. BSA or AGE-BSA served as a control in this experiment. 
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The uptake of native OVA, Pyr-OVA and AGE-OVA by mannan-treated BMDCs was essentially 
reduced compared to non-treated cells (figure 32). Pre-treatment of SR-A
-/-
 cells with mannan nearly 
completely inhibited the uptake of all OVA samples, although slight levels of Pyr-OVA and 
AGE-OVA uptake were observed. The difference in the reduction of uptake after mannan-treatment by 
wt and SR-A
-/-
 BMDCs in figure 32 might be explained by a strong uptake of Pyr-OVA and 
AGE-OVA by the SR-AI/II and thus, SR-AI/II seems to be compensating for the block of the MR. 
 
 
Figure 32: Uptake of OVA samples by BMDCs after inhibition of the MR with mannan. Wt or SR-A
-/-
 BMDCs were 
treated with 3 mg/ml of mannan for 30 min prior to incubation with 5 µg/ml of FITC-labelled native OVA, Pyr-OVA or 
AGE-OVA for 15 min. FITC intensity of CD11b
+
CD11c
+
 cells was analyzed with flow cytometry. Grey areas represent 
BMDCs cultured without antigen. 
 
To examine whether mannan inhibit the interaction of natural mannose residues in native OVA with 
the MR specifically, BSA samples were used, as this protein does not possess mannose residues. A 
strong uptake of AGE-BSA by non-treated BMDCs was observed, whereas native BSA and inc. BSA 
were not taken up by the cells (figure 33). Thus, the uptake of AGE-BSA by BMDCs is only mediated 
by AGE-binding receptors. Unexpectedly, pre-treatment of wt BMDCs with mannan reduced the 
uptake of AGE-BSA. The reduced uptake of AGE-BSA was also observed in SR-A
-/-
 BMDCs 
pre-treated with mannan. These results suggest that the MR could be involved in the uptake of 
AGE-BSA and AGE-OVA by association with glycation structures. 
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Figure 33: Uptake of BSA samples by BMDCs after inhibition of the MR with mannan. Wt or SR-A
-/-
 BMDCs were 
treated with 3 mg/ml of mannan for 30 min prior to incubation with 5 µg/ml of FITC-labelled native BSA, inc. BSA or 
AGE-BSA for 15 min. FITC intensity of CD11b
+
CD11c
+
 cells was analyzed with flow cytometry. Grey areas represent 
BMDCs cultured without antigen. 
 
 
4.1.6 Role of SR-AI/II in the activation of OVA-specific CD4+ T-cells by Pyr-OVA 
The results obtained so far suggest that the uptake of Pyr-OVA by BMDCs is in part mediated by 
SR-AI/II. Next, the impact of the SR-AI/II-mediated uptake of the OVA samples by DCs on 
CD4
+
 T-cell activation was investigated. To investigate the impact, a co-culture system of SR-A
-/-
 
BMDCs and OVA-specific CD4
+
 T-cells isolated from OT-II mice was used. Either wt or SR-A
-/-
 
BMDCs were primed with native OVA, Pyr-OVA or AGE-OVA before the addition of OT-II cells to 
avoid the putative interaction of antigen with CD4
+
 T-cells. IL-2 production served as an indicator for 
T-cell activation. 
As shown in figure 34, BMDCs primed with Pyr-OVA or AGE-OVA induced higher levels of IL-2 
production in their culture supernatants compared to those primed with native OVA. This strong T-cell 
activation by Pyr-OVA and AGE-OVA was reduced by the use of SR-A
-/-
 BMDCs, instead of wt 
BMDCs. These results suggest that SR-AI/II plays a crucial role in the uptake of Pyr-OVA and 
AGE-OVA by BMDCs and subsequent CD4
+
 T-cell activation. 
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Figure 34: IL-2 production by OT-II cells cultured with SR-A
-/-
 or wt BMDCs primed with OVA samples. 
CD4
+
 T-cells were isolated from OT-II mice. Syngeneic BMDCs were incubated with 20 µg/ml or 200 µg/ml of native 
OVA, Pyr-OVA or AGE-OVA for 3 h and washed. OT-II cells and OVA sample-primed BMDCs were cultured for 20 h. 
The concentration of IL-2 in the cell culture supernatants was then determined by ELISA. * p < 0.05, ** p < 0.01 (n.d.: not 
detectable; below detection limit of 0.02 pg/ml). 
 
 
4.1.7 Localization of Pyr-OVA and AGE-OVA in intracellular compartments after antigen 
uptake 
Antigens taken up by receptor-mediated endocytosis, as in the case of OVA, are processed for 
antigen-presentation in intracellular compartments, like endosomes or lysosomes. Next, it was tried to 
verify the receptor-mediated endocytosis of OVA samples by BMDCs. 
For this purpose, wt BMDCs were incubated with FITC-labelled Pyr-OVA or AGE-OVA for 15 min. 
After fixation and permeabilization, the cells were stained for early endosomes using a mAb specific 
for the early endosomal antigen-1 (EEA-1) followed by staining of the cell nucleus with DAPI. The 
analysis of the putative co-localization of the modified OVAs with EEA-1 was performed using a 
confocal microscope. 
The yellow spots in figure 35 show co-localization of EEA-1 with Pyr-OVA or AGE-OVA, 
respectively. These findings suggest that Pyr-OVA and AGE-OVA are transported to endosomal 
compartments in BMDCs after antigen uptake. 
 
 
 
IL
-2
 [
n
g
/m
l]
0 20 200 20 200 20 200
0
1
2
3
4
5 wt BMDCs
SR-A-/- BMDCs
n.d.
[µg/ml]
native
OVA
Pyr-OVA AGE-OVA
*
** **
 Results and Discussion 72 
 
 
Figure 35: Co-localization of Pyr-OVA or AGE-OVA with EEA-1 in BMDCs. Wt BMDCs were incubated with 
FITC-labelled Pyr-OVA or AGE-OVA (green) for 15 min, then fixed with 4 % PFA and stained using anti-EEA-1 mAb 
(red). The cell nucleus was stained with DAPI (blue). The cells were analyzed using a confocal microscope. 
 
 
4.1.8 Influence of glycation on the potential allergenicity of OVA using a mouse model of 
intestinal allergy 
Next, it was investigated whether glycation also influences the potential allergenicity (i.e. ability to 
induce sensitization by triggering IgE production and to cause clinical symptoms in an allergic 
individual) of OVA using a mouse model of intestinal allergy. The immunization protocol of the 
model, which was established by Burggraf et al., is shown in figure 36.(101) Briefly, BALB/c mice 
were intraperitoneally (i.p.) sensitized with native OVA, Pyr-OVA or AGE-OVA in combination with 
ALUM, an adjuvant inducing TH2-directed immune responses, twice at a two week interval. Two 
weeks after the last sensitization, the mice were fed with a diet containing egg white (EW-diet) for one 
week. 
After the i.p. sensitization, the levels of OVA-specific IgE, IgG1 and IgG2a antibodies in the sera were 
determined by ELISA. During feeding the EW-diet, clinical symptoms, i.e. loss of body weight and 
drop in body core temperature, of the mice were monitored. Furthermore, after the feeding, the mice 
were euthanized for isolation of CD4
+
 T-cells from the gut draining lymphoid organ, i.e. the 
mesenteric lymph nodes (MLN). The isolated MLN-derived CD4
+
 T-cells were used to assess 
OVA-specific T-cell responses in the tissues. 
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Figure 36: Immunization protocol of a mouse model of intestinal allergy. BALB/c mice (n=6) were i.p. sensitized with 
10 µg of native OVA, Pyr-OVA or AGE-OVA together with 1 mg of ALUM twice. One week after each sensitization 
blood was taken from the mice. Two weeks after the last sensitization, the mice were fed with a diet containing egg white 
(EW-diet). On day 7 of the EW-diet, the mice were euthanized to harvest the MLN for T-cell assays. 
 
 
4.1.8.1 Levels of OVA-specific IgE, IgG1 and IgG2a in mice sensitized with OVA modified 
with glycation structure 
In mice, IL-4, a TH2-related cytokine, induces antibody class switch to IgE and IgG1 in B-cells, while 
IFN-γ, a TH1-related cytokine, induces class switch to IgG2a. To assess the potential allergenicity of 
the OVAs modified with glycation structures, the serum levels of IgE, IgG1 and IgG2a antibodies in 
mice, who received i.p. sensitization with native OVA, Pyr-OVA or AGE-OVA were measured by 
ELISA. 
After the first i.p. sensitization with OVA samples, IgE antibodies were not detectable in all groups. 
However, by the second sensitization, serum IgE levels of mice sensitized with Pyr-OVA or 
AGE-OVA were remarkably enhanced and were higher than those of mice sensitized with native OVA 
(figure 37A). The result suggests that Pyr-OVA and AGE-OVA could have a higher ability to induce 
sensitization than native OVA. 
OVA-specific IgG1 antibodies were detected in the sera of mice from all groups after the first i.p. 
sensitization. The serum IgG1 levels of mice sensitized with Pyr-OVA or AGE-OVA were higher than 
those of mice sensitized with native OVA (figure 38A). After the second sensitization, serum IgG1 
levels of mice sensitized with Pyr-OVA or AGE-OVA were rather reduced, compared to those of mice 
sensitized with native OVA. The result suggest that, in the i.p. sensitization setting, production of IgG1 
antibodies was saturated by the second sensitization with Pyr-OVA and AGE-OVA due to its high 
immunogenicity. Serum OVA-specific IgG2a antibodies were detected in mice from all groups only 
after the second sensitization. The serum levels of IgG2a antibodies in mice sensitized with Pyr-OVA 
or AGE-OVA tended to be higher than those of mice sensitized with native OVA, although only 
marginal levels were detected (figure 39A). These results suggest that Pyr-OVA and AGE-OVA are 
capable of inducing higher antibody production than native OVA in the sensitization phase of allergy. 
Next, the serum antibody levels in the sensitized mice after EW-diet feeding were measured. EW-diet 
feeding induced a strong boost in the levels of OVA-specific IgE and IgG1 antibodies (figures 37B and 
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38B), whereas OVA-specific IgG2a antibodies stayed at marginal levels (figure 39B). Here, no 
significant differences in the levels found after sensitization were observed. This could be due to the 
high amount of native OVA contained in the EW-diet, which could trigger a strong booster effect on 
the OVA-specific antibody production and therefore, the levels of IgE and IgG1 antibodies became 
comparable among all groups. 
 
 
Figure 37: OVA-specific IgE antibody production in mice sensitized with OVA samples and fed EW-diet. (A) Mice 
were i.p. sensitized with native OVA, Pyr-OVA or AGE-OVA together with ALUM as an adjuvant twice. (B) Two weeks 
after the last sensitization, the mice were fed a diet containing egg white (EW-diet). Sera were collected one week after 
each sensitization and after 7d of feeding. Levels of OVA-specific IgE antibodies were determined by ELISA. Each symbol 
represents the data of one individual mouse. * p < 0.05, ** p < 0.01, *** p < 0.001 (n.d.: not detectable; below detection 
limit of 0.1 U/ml). 
 
Figure 38: OVA-specific IgG1 antibody production in mice sensitized with OVA samples and fed EW-diet. (A) Mice 
were i.p. sensitized with native OVA, Pyr-OVA or AGE-OVA together with ALUM as an adjuvant twice. (B) Two weeks 
after the last sensitization, the mice were fed a diet containing egg white (EW-diet). Sera were collected one week after 
each sensitization and after 7d of feeding. Levels of OVA-specific IgG1 antibodies were determined by ELISA. Each 
symbol represents the data of one individual mouse. * p < 0.05, ** p < 0.01 (n.d.: not detectable; below detection limit of 
0.005 U/ml). 
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Figure 39: OVA-specific IgG2a antibody production in mice sensitized with OVA samples and fed EW-diet. 
(A) Mice were i.p. sensitized with native OVA, Pyr-OVA or AGE-OVA together with ALUM as an adjuvant twice. 
(B) Two weeks after the last sensitization, the mice were fed a diet containing egg white (EW-diet). Sera were collected 
one week after each sensitization and after 7d of feeding. Levels of OVA-specific IgG2a antibodies were determined by 
ELISA. Each symbol represents the data of one individual mouse. (n.d.: not detectable; below detection limit of 
0.005 U/ml). 
 
 
4.1.8.1.1 Binding of IgE in sera of Pyr-OVA- or AGE-OVA-sensitized mice to glycation 
structures 
Next, it was investigated whether sensitization of BALB/c mice with Pyr-OVA or AGE-OVA, induces 
production of IgE antibodies specific for glycation structure(s). For this purpose, ELISA was 
performed using plates coated with 100 µg/ml of AGE-OVA or AGE-BSA. Protein conformation and 
the primary sequence of OVA and BSA are different. Therefore, by using AGE-BSA it is possible to 
examine whether sera in AGE-OVA-sensitized mice contained antibodies binding to glycation 
structure(s). 
As shown in figure 40, higher levels of IgE in AGE-OVA-sensitized mice and slightly increased levels 
of IgE in Pyr-OVA-sensitized mice were detected compared to IgE levels in native OVA-sensitized 
mice when ELISA plates coated with native OVA or AGE-OVA were used. No IgE binding to 
AGE-BSA was detected when ELISA plates were coated with this control glycation product without 
OVA protein (data not shown). The result suggests that Pyr-OVA and AGE-OVA would not induce 
antibodies specific for glycation structures. 
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Figure 40: Detection of IgE antibodies binding to glycation structures by ELISA. After the second i.p. sensitization 
with native OVA, Pyr-OVA or AGE-OVA together with ALUM, blood was taken from the mice and the sera were 
prepared. The sera were then applied to ELISA plates coated with (A) native OVA or (B) AGE-OVA. IgE binding to 
coated materials was detected using Biotin-anti-mouse IgE mAb in combination with Streptavidin-HRP. Each symbol 
represents the data of one individual mouse. (n.d.: not detectable; below detection limit of 0.1 U/ml). 
 
 
4.1.8.2 Clinical symptoms in mice sensitized with Pyr-OVA or AGE-OVA 
It was of particular importance to investigate whether the elevated levels of IgE antibodies by 
Pyr-OVA or AGE-OVA sensitization enhance clinical symptoms. Therefore, the sensitized animals 
were fed with EW-diet and their body weight as well as their body core temperature was monitored. 
EW-diet feeding for four days induced strong loss of body weight in all sensitization groups 
(figure 41A). Although the differences were not remarkable, there was a tendency that a stronger 
weight loss was induced in Pyr-OVA- or AGE-OVA-sensitized mice compared to native 
OVA-sensitized mice. Moreover, on day four of EW-diet feeding the lowest body core temperature 
was detected in all sensitized mice (figure 41B). Body core temperature of Pyr-OVA- or 
AGE-OVA-sensitized mice was considerably lower than that of native OVA-sensitized mice. 
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Figure 41: Changes of (A) body weight and (B) body core temperature in mice sensitized with OVA samples and fed 
EW-diet. Two weeks after the second i.p. sensitization with native OVA, Pyr-OVA or AGE-OVA together with ALUM, 
BALB/c mice were fed EW-diet. (A) Body weight and (B) body core temperature of sensitized and fed mice were 
monitored. Each symbol represents the data of one individual mouse. 
 
Taken together, strong clinical symptoms were observed in mice sensitized with OVA samples during 
feeding the EW-diet and the strongest symptoms were found in Pyr-OVA- and AGE-OVA-sensitized 
mice. These results suggest that modification with pyrraline or glycation structures could enhance the 
allergenic potency of OVA. 
 
 
4.1.8.3 Influence of glycation structure on the activation of MLN-derived CD4+ T-cells from 
allergic mice 
Besides humoral immune responses and clinical symptoms, the T-cell immune response in the mice 
sensitized with the OVAs modified with glycation structures was assessed. The mice were sacrificed 
after one week of EW-diet feeding and their MLN were isolated. Proliferation as well as cytokine 
production by MLN-derived CD4
+
 T-cells upon in vitro stimulation with OVA samples was then 
measured. 
CD4
+
 T-cells from mice sensitized with native OVA, Pyr-OVA or AGE-OVA showed higher 
proliferation in response to Pyr-OVA or AGE-OVA (figure 42). The proliferation levels of MLN 
CD4
+
 T-cells in response to OVA samples were similar among the groups. Enhanced IL-4 production, 
particular against Pyr-OVA, was observed by MLN CD4
+
 T-cells from mice sensitized with native 
OVA or Pyr-OVA (figure 43). The lower proliferation against the high concentration of Pyr-OVA 
(1000 µg/ml) compared to the high levels of IL-4 might be explained by an over-stimulation of the 
cells shortening the cell viability, because IL-4 was measured after 72 h of culture, whereas 
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proliferation was measured after 96 h of culture. IL-4 production against AGE-OVA was also 
enhanced by MLN CD4
+
 T-cells from mice sensitized with AGE-OVA. These results suggest that 
Pyr-OVA and AGE-OVA could have a higher T-cell immunogenicity in vivo, where polyclonal T-cells 
exist and react to allergens. 
 
 
Figure 42: Proliferation of MLN-derived CD4
+
 T-cells from allergic mice sensitized with OVA samples and fed 
EW-diet. BALB/c mice were sensitized with (A) native OVA, (B) Pyr-OVA or (C) AGE-OVA together with ALUM twice 
and fed EW-diet for seven days. CD4
+
 T-cells were then isolated from the MLN of the mice and co-cultured with 
mitomycin-treated syngeneic splenocytes in the presence of either form of OVA for 96 h. Proliferation of CD4
+
 T-cells was 
assessed by incorporation of [methyl-
3
H]-thymidine during the last 20 h of culture. (ND: not determined; Pyr-OVA was not 
included for stimulation in panel C due to the limited amount of this material). 
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Figure 43: IL-4 production of MLN-derived CD4
+
 T-cells from mice sensitized with OVA samples and fed EW-diet. 
BALB/c mice were sensitized with (A) native OVA, (B) Pyr-OVA or (C) AGE-OVA together with ALUM twice and fed 
EW-diet for seven days. CD4
+
 T-cells were then isolated from the MLN of the mice and co-cultured with 
mitomycin-treated syngeneic splenocytes in the presence of either form of OVA for 72 h. The concentration of IL-4 in the 
cell culture supernatants was determined by ELISA. (n.d.: not detectable, below detection limit of 0.01 pg/ml; ND: not 
determined; Pyr-OVA was not included for stimulation in panel C due to the limited amount of this material). 
 
To summarize, re-stimulation of MLN-derived CD4
+
 T-cells from allergic mice with Pyr-OVA or 
AGE-OVA resulted in enhanced proliferation and IL-4 production compared to cells incubated with 
native OVA. Using in vivo TH2-polarized CD4
+
 T-cells these data confirm the enhanced T-cell 
immunogenicity of Pyr-OVA and AGE-OVA.  
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4.1.9 Discussion 
 
4.1.9.1 Modification of OVA with pyrraline enhances its CD4+ T-cell immunogenicity in 
vitro  
In this study, we found that modification of OVA with pyrraline, but not with CEL, CML or 
arginine-derivatives like MG-H1, enhances the CD4
+
 T-cell immunogenicity of this model food 
allergen. Pyr-OVA also enhanced TH1 and TH17 cytokine production by OT-II cells and TH2 cytokine 
production by DO11.10 cells. These results indicate that pyrraline modification of OVA does not 
induce a bias in T-cell polarization, but does enhance overall T-cell activation, since OT-II cells tend 
to induce TH1- or TH17-type responses, whereas DO11.10 cells tend to induce a TH2-related 
phenotype. 
Although CD8
+
 T-cells are not the main effector cells to trigger allergic responses, the influence of 
glycation on the CD8
+
 T-cell immunogenicity of OVA was of interest, because this provide some 
insight into the delivery pathway of glycated allergens for antigen presentation in DCs. We found that 
CD8
+
 T-cell immunogenicity of OVA is not influenced by glycation. The OVAs modified with 
glycation structure, AGE-OVA and native OVA induced similar levels of IL-2 and IFN-γ production 
by OT-I-derived CD8
+
 T-cells. These results suggest that Pyr-OVA and AGE-OVA are more 
efficiently delivered to the MHC class II loading pathway, not to the MHC class I loading pathway, in 
DCs and this subsequently enhances the activation of OVA-specific CD4
+
 T-cells. 
 
 
4.1.9.2 BMDC maturation is not influenced by modification of OVA with Maillard reaction 
products 
The maturation status of the BMDCs, which influences T-cell activation, was not affected by the 
OVAs modified with glycation structures. Expression of the co-stimulatory molecules CD40, CD80 
and CD86, as well as of MHC class II molecules on the cell surface was not upregulated by incubation 
of DCs with any of the OVA samples. Incubation of the cells with either OVA sample did not induce 
detectable levels of IL-6 production by DCs. Thus, the enhanced CD4
+
 T-cell immunogenicity of 
Pyr-OVA and AGE-OVA is not due to induction of the DC maturation process by the OVA samples. 
In contrast, Buttari et al. showed that AGEs of plasma β2-glycoprotein I (β2GPI) induce maturation of 
human monocyte-derived DCs.(104) In their study, DC maturation was induced via interaction of 
AGEs with RAGE followed by activation of the nuclear factor-κB signalling pathway.(104) In 
addition, AGE-modification resulted in a switch of the T-cell stimulatory capacity of β2GPI towards 
TH2 polarization.(104) In our study, Pyr-OVA and AGE-OVA enhance TH1-, TH2- and TH17-cytokine 
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production by OT-II cells and DO11.10 cells, indicating that T-cell polarization is not induced by the 
glycated samples. The discrepancy might be explained by a different profile of glycation structures 
present in AGE-OVA and AGE-β2GPI, because AGE-OVA was prepared by wet incubation of OVA 
with glucose at 50 °C, whereas dry incubation of β2GPI with glucose at 37 °C was chosen for 
AGE-β2GPI. Another explanation might be a varying surface receptor expression by the DCs. Hence, 
Ilchmann et al. showed that RAGE expression was not detected on the surface of BMDCs, whereas a 
high level of RAGE has been observed on human monocyte-derived DCs.(71, 104) 
Taken together, the enhanced CD4
+
 T-cell immunogenicity of Pyr-OVA and AGE-OVA is not caused 
by a promotion of the DC maturation process due to the modification of OVA with Maillard reaction 
products. 
 
 
4.1.9.3 Pyr-OVA and AGE-OVA are highly taken up by BMDCs 
Besides maturation, the levels of antigen uptake by APCs have a large impact on subsequent T-cell 
activation. We found that Pyr-OVA and AGE-OVA were taken up by BMDCs to a stronger extent 
than native OVA. No enhanced uptake of CE-OVA, CM-OVA or MGO-OVA by BMDCs was 
observed. These results suggest that the enhanced uptake of Pyr-OVA and AGE-OVA by DCs lead to 
the enhanced T-cell activation by Pyr-OVA and AGE-OVA. 
Recently, Rupa et al. showed that glycation of OVA with mannose (OVAMan) reduced the allergen 
uptake by DCs, whereas glycation with glucose (OVAGlu) did not alter the uptake level by DCs.(109) 
As a consequence, OVAMan induced less IL-2 production by naive CD4
+
 T-cells compared to native 
OVA or OVAGlu.(109) The findings were explained by a reduced α-helical configuration of 
OVAMan, but not of OVAGlu, compared to native OVA.(109) The partial denaturation might have 
destroyed receptor binding sites important for antigen uptake, since it has been shown that minor 
changes in the secondary structure of OVA influences protein function.(32, 109) In our measurements 
of the CD-spectra, the glycated OVAs retained a similar secondary structure as does native OVA. The 
discrepancy between our and their observations might be explained by differences in the levels and the 
profiles of glycation. AGE-OVA was prepared in phosphate buffer with glucose at 50 °C, whereas dry 
incubation at 100 °C for a shorter period was selected in the study of Rupa et al.(109) Around 69.8 % 
of lysine residues are modified in AGE-OVA in our study, in comparison to 95.4 % in OVAMan and 
93.5 % in OVAGlu, respectively.(109) The different incubation conditions could generate different 
types of glycation structures. However, taken together both studies show that the uptake levels of 
glycated allergens by APCs influence the overall immunogenicity of the protein. 
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4.1.9.3.1 SR-AI/II mediates the enhanced uptake of Pyr-OVA and AGE-OVA by DCs 
The identification of the receptors involved in the enhanced antigen uptake of Pyr-OVA and 
AGE-OVA was of particular interest, since SR-AI/II, CD36, SR-BI and galectin-3 are known 
AGE-binding receptors. We found that uptake of Pyr-OVA or AGE-OVA by SR-A
-/-
 DCs was reduced 
compared to wt DCs showing that SR-AI/II mediates the uptake of Pyr-OVA and AGE-OVA. In 
contrast, the receptor deficiency did not impair the uptake of native OVA, CE-OVA, CM-OVA or 
MGO-OVA by DCs. The results suggest that SR-AI/II binds to pyrraline, but not to CEL, CML or 
MG-H1. 
SR-AI/II is a trimer comprised of a transmembrane domain, a spacer region, a helical coiled-coil 
domain, a collagenous domain and a C-terminal cysteine-rich domain.(48) A variety of ligands, such 
as oxLDL or acLDL and chemically modified proteins including AGEs, bind to the collagenous 
domain of SR-AI/II.(48, 55) Previously, Nagai et al. showed that MGO-derived AGEs conjugated to 
BSA were not taken up by RAW264.7 cells, a murine macrophage-derived cell line expressing 
SR-AI/II.(84) Furthermore, no endocytosis of glyoxal-modified BSA, which contained high amounts 
of CML, by RAW264.7 cells was observed.(84) The results support the hypothesis that SR-AI/II does 
not bind the glycation structures CML and MG-H1. 
SR-AI/II has been suggested to transfer its ligands to the MHC class II loading pathway for efficient 
T-cell activation.(110, 111) Consistent with this SR-AI/II function pyrraline modification enhances the 
CD4
+
 T-cell immunogenicity, but not the CD8
+
 T-cell immunogenicity of OVA. We could show that 
SR-AI/II is an important mediator of the enhanced CD4
+
 T-cell immunogenicity of Pyr-OVA and 
AGE-OVA. This result suggests that the association of SR-AI/II with glycated food allergens might 
have an influence on the sensitization phase of allergy, because TH2-cells, a subset of CD4
+
 T-cells, 
are crucial for an efficient IgE production by B-cells. 
 
 
4.1.9.3.2 The mannose receptor plays a role in the uptake of Pyr-OVA and AGE-OVA by 
DCs 
It is well known that the MR binds to natural mannose residues in OVA. Blocking of the MR with 
mannan resulted in a reduced uptake of native OVA, Pyr-OVA and AGE-OVA by SR-A
-/-
 DCs. At 
first, it was thought that the reduced DC uptake of the OVA samples by mannan treatment was only 
due to inhibition of the binding to the natural mannose residues. However, we found that the uptake of 
AGE-BSA by BMDCs was also reduced after blockage of the MR with mannan, although native BSA 
does not possess natural ligands of the MR. These results suggest that the MR might be an 
AGE-binding receptor and contributes to the uptake of Pyr-OVA and AGE-OVA by recognition of the 
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glycation structures. However, a previous study by Burgdorf et al. showed that the MR delivers its 
ligands to the MHC class I loading pathway for CD8
+
 T-cell activation.(59) Notably, only the 
CD4
+
 T-cell immunogenicity, but not the CD8
+
 T-cell immunogenicity, of OVA was enhanced by 
modification of OVA with pyrraline or AGEs. Moreover, the enhanced OVA-specific CD4
+
 T-cell 
activation by Pyr-OVA and AGE-OVA was significantly attenuated in co-culture with SR-A
-/-
 
BMDCs. These results suggest that SR-AI/II plays a crucial role in the uptake of Pyr-OVA and 
AGE-OVA by wt BMDCs, which lead to an efficient delivery to the MHC class II loading pathway for 
antigen presentation and therefore, this enhances OVA-specific CD4
+
 T-cell activation. 
We also observed that mannan-treated SR-A
-/-
 DCs took up Pyr-OVA, AGE-OVA and AGE-BSA to a 
small extent. The results suggest that another receptor could be involved in the endocytosis of the 
glycated samples by DCs, although it could only play a minor role in the uptake of Pyr-OVA and 
AGE-OVA. The receptors galectin-3, SR-BI or CD36, do not play a role, because their inhibition 
using specific inhibitors or blocking antibodies did not reduce the uptake of the OVA samples by 
SR-A
-/-
 cells. 
In summary, the strong uptake of Pyr-OVA and AGE-OVA is mediated by SR-AI/II and the MR, and 
another yet unknown receptor could be partially involved in the endocytosis of Pyr-OVA and 
AGE-OVA. 
 
 
4.1.9.4 Enhanced allergenic potency of Pyr-OVA and AGE-OVA 
IgE antibodies, key molecules to induce type I allergic reactions, are produced by B-cells in assistance 
with TH2-cells, a subset of CD4
+
 T-cells. Since Pyr-OVA and AGE-OVA displayed a higher 
CD4
+
 T-cell immunogenicity than native OVA, we then assessed the sensitization ability of these 
OVA samples. Pyr-OVA and AGE-OVA induced higher levels of OVA-specific IgE antibodies than 
native OVA in BALB/c mice when i.p. sensitized together with ALUM. Moreover, a strong loss of 
body weight and drop in body core temperature was observed in mice sensitized with Pyr-OVA or 
AGE-OVA compared to native OVA-sensitized mice when they were fed with EW-diet containing 
high amounts of OVA. These results suggest that AGE-OVA and Pyr-OVA possess a higher allergenic 
potency than native OVA. 
Among the CD4
+
 T-cell subsets, TH2-cells play a crucial role in the induction of IgE production by 
B-cells. Thus, the question was raised whether or not the enhanced allergenic potency is due to a 
predominant induction of TH2-cells by the glycation structures. However, it is very unlikely, because 
in vitro co-culture assay of BMDCs with OT-II or DO11.10 cells suggests that AGE-OVA and 
Pyr-OVA enhance both TH1 and TH2 cytokine immune responses. Previously, Bhatia et al. reported 
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that a chemically modified antigen bound by SR-AI/II induced dominant TH1 immune responses.(112) 
However, the levels of OVA-specific IgG2a antibodies, which are a TH1-type of the IgG subclasses, 
were only at marginal levels in all groups of mice. Moreover, the strong TH2 immune response of the 
mice from all groups was supported by a strong production of IL-4 by CD4
+
 T-cells and a strong 
proliferation of MLN-derived CD4
+
 T-cells isolated from the allergic mice after in vitro re-stimulation 
with OVA. By assessing the cell-based immune response of the allergic mice, we found that 
modification of OVA with pyrraline or AGEs enhances the activation of polyclonal CD4
+
 T-cells 
compared to native OVA suggesting a higher in vivo CD4
+
 T-cell immunogenicity of Pyr-OVA and 
AGE-OVA. These results indicate that the enhanced CD4
+
 T-cell immunogenicity of Pyr-OVA and 
AGE-OVA could subsequently induce the enhanced IgE production and clinical symptoms in the mice 
sensitized with Pyr-OVA or AGE-OVA, respectively. 
 
In summary, a putative molecular mechanism of the enhanced CD4
+
 T-cell immunogenicity and 
allergenic potency of Pyr-OVA and AGE-OVA can be proposed (figure 44). Briefly, the strong 
SR-AI/II-mediated uptake of Pyr-OVA and AGE-OVA compared to native OVA leads to a more 
efficient delivery to the MHC class II loading pathway for antigen presentation. In turn, Pyr-OVA and 
AGE-OVA induce stronger activation and cytokine production by allergen-specific CD4
+
 T-cells. In 
the allergic status, a TH2-type cytokine milieu dominates in the immune system. Thus, the activation of 
TH2-cells, a subset of CD4
+
 T-cells, by Pyr-OVA and AGE-OVA subsequently induces a strong B-cell 
activation and class switch in B-cells to produce allergen-specific IgE antibodies. The higher levels of 
IgE antibodies induced by Pyr-OVA and AGE-OVA compared to the unmodified allergen finally 
cause stronger clinical symptoms. 
 
  
 
Figure 44: Molecular mechanism of the enhanced CD4
+
 T-cell immunogenicity and allergenic potency of Pyr-OVA 
and AGE-OVA. 
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In conclusion, AGE- and pyrraline-modification by the Maillard reaction could be capable of 
enhancing the CD4
+
 T-cell immunogenicity and subsequently the potential allergenicity of food 
allergens. High levels of pyrraline have been detected in commercially available roasted peanuts, a 
clinically relevant allergenic food.(70) The high contents of pyrraline in roasted peanuts together with 
the enhancing effect of pyrraline on the allergenicity might pose a strong risk for peanut allergic 
patients. Thus, the modification of food allergens by the Maillard reaction needs to be considered for 
food safety and allergy diagnosis, where extracts of raw foods or unprocessed purified allergens are 
usually used. Supplementary, the glycation profiles of common processed allergenic foods need to be 
identified, because only very limited information is available so far. 
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4.2 Establishment of a human cell culture system to assess the immunogenic 
potency of a glycated food allergen 
 
4.2.1 Introduction 
In the previous chapter, we found that SR-AI/II mainly mediates the uptake of AGE-OVA by murine 
DCs. To verify this finding in this chapter, we aimed to establish a cell culture system of human DCs 
or macrophages. Recent studies have shown that both DCs and macrophages are professional APCs, 
which take up antigens and present the processed antigens by MHC molecules to naive T-cells and 
hence, both cell types need to be considered for studying the immunogenicity of glycated food 
allergens. In humans, two types of macrophages are present, M1 and M2 macrophages. M1 
macrophages have a pro-inflammatory phenotype and are involved in TH1-type immune responses, 
whereas M2 cells have an anti-inflammatory phenotype, but are also regarded as model APCs to assist 
in TH2-type responses. The monocyte-derived DCs as well as M1 and M2 macrophages were 
characterized regarding the surface expression of AGE-binding receptors, e.g. SR-AI/II, CD36 and 
SR-BI. The uptake of AGE-OVA by these cells was also investigated. 
 
 
4.2.2 Characterization of human DCs 
For the in vitro generation of human DCs, PBMCs were isolated from buffy coat by density gradient 
centrifugation. Magnetic separation was then performed to separate magnetically labelled 
CD14
+
 monocytes from other lymphocytes. Differentiation of the CD14
+
 monocytes into immature 
DCs (iDCs) was induced by culturing the cells in the presence of IL-4 and GM-CSF. Maturation of 
iDCs was induced by a cocktail of IL-1, TNF- and PGE2. 
Both iDCs and mature DCs (mDCs) were characterized for the expression of the co-stimulatory 
molecules CD80 and CD86, and of HLA-DR as well as of the MR, SR-AI/II, CD36 and SR-BI. The 
expression of these receptors is of interest, first, because the MR and SR-AI/II play a pivotal role in the 
uptake of AGE-OVA by murine DCs and second, because CD36 and SR-BI are known to bind AGEs. 
Co-stimulatory molecule and receptor expression was analyzed with flow cytometry. 
Figure 45 shows that the co-stimulatory molecules CD80 and CD86 were expressed on the surface of 
iDCs and were upregulated after induction of maturation. HLA-DR is also highly expressed by both 
iDCs and mDCs. The expression of the MR, CD36 and SR-BI, but not of SR-AI/II, was detected on 
the cell surface of iDCs (figure 46). The expression levels of the MR, CD36 and SR-BI were reduced 
on the cell surface of mDCs. It is known that DCs reduce the expression of receptors capturing 
antigens, e.g. scavenger receptors and the MR, to gain T-cell stimulatory capacity in the course of 
 Results and Discussion 87 
maturation.(75) These results suggest that proper iDCs as well as mDCs were generated in the in vitro 
cell culture system. 
 
 
 
Figure 45: Expression of co-stimulatory molecules by human dendritic cells. Human immature DCs (iDCs) and mature 
DCs (mDCs) were generated from PBMCs and stained using anti-CD80, CD86 or HLA-DR mAb. The expression levels of 
the co-stimulatory molecules were assessed with flow cytometry. Grey areas represent unstained cells and black lines 
indicate cells treated with the respective isotype control antibody. 
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Figure 46: Receptor expression by human dendritic cells. Human immature DCs (iDCs) and mature DCs (mDCs) were 
generated from PBMCs and stained using anti-MR, SR-AI/II, CD36 or SR-BI mAb. The expression levels of the receptors 
were assessed with flow cytometry. Grey areas represent unstained cells and black lines indicate cells treated with the 
respective isotype control antibody. 
 
 
4.2.3 Analysis of the uptake of the OVA samples by human DCs 
The uptake of the glycated OVA samples by DCs has a great impact on the T-cell immunogenicity of 
the respective protein in the murine system. Thus, the uptake levels of glycated OVA and control OVA 
by human iDCs was assessed. To determine the optimal point in time for uptake measurement, human 
DCs were incubated for 15 min, 60 min or 240 min with FITC-labelled native OVA, inc. OVA or 
AGE-OVA. As a measure for the antigen uptake, the FITC intensity was determined with flow 
cytometry. 
After 15 min of incubation (data not shown) and 60 min incubation (figure 47A) OVA samples were 
taken up by iDCs at similar levels. The prolongation of the incubation time to 240 min (figure 47B) 
enhanced the uptake of AGE-OVA by iDCs. 
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Figure 47: Uptake of native OVA, inc. OVA and AGE-OVA by human iDCs.  PBMC-derived iDCs were incubated for 
(A) 60 min or (B) 240 min with FITC-labelled native OVA, inc. OVA or AGE-OVA. FITC intensity of the cells was 
determined with flow cytometry. 
 
 
4.2.4 Characterization of human macrophages 
Besides DCs, macrophages are prominent APCs and need to be considered for studies regarding the 
immunogenicity of the modified OVAs in human cells. In human macrophages, there are the two 
subsets M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophages, which can both be 
generated in vitro by application of different cytokines. 
Therefore, PBMC-derived M1 or M2 macrophages were prepared and characterized. The surface 
expression of the MR, SR-AI/II, CD36 and SR-BI was analyzed with flow cytometry. 
All receptors of interest were detected on the cell surface of both M1 and M2 macrophages (figure 48). 
The MR was expressed at higher levels on the surface of M1 macrophages compared to M2 
macrophages. In contrast, SR-AI/II and SR-BI were expressed at higher levels on the surface of M2 
macrophages compared to the M1 phenotype. The expression levels of CD36 were comparable 
between M1 and M2 cells. 
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Figure 48: Receptor expression by M1 and M2 macrophages.  Human M1 and M2 macrophages were generated from 
PBMCs and stained using anti-MR, SR-AI/II, CD36 or SR-BI mAb. The expression levels of the receptors were assessed 
with flow cytometry. Grey areas represent unstained cells. 
 
 
4.2.5 Analysis of the uptake of the OVA samples by human macrophages 
Next, the antigen uptake was assessed by incubating M1 or M2 macrophages with FITC-labelled 
AGE-OVA or native OVA for 15 min or 60 min. 
Figure 49 shows a comparable intensity of FITC in M1 macrophages incubated with FITC-native 
OVA and FITC-AGE-OVA after 15 min or 60 min incubation, respectively, indicating that native 
OVA and AGE-OVA were taken up to a similar extent by M1 macrophages. In contrast, an enhanced 
uptake of AGE-OVA compared to native OVA by M2 macrophages was observed after 15 min 
incubation. The enhanced uptake of AGE-OVA was more pronounced after prolongation of the 
incubation time to 60 min. 
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Figure 49: Uptake of native OVA and AGE-OVA by human M1 and M2 macrophages.  PBMC-derived M1 or M2 
macrophages were incubated for (A) 15 min or (B) 60 min with FITC-labelled native OVA or AGE-OVA. FITC intensity 
of the cells was determined with flow cytometry. Grey areas represent cells cultured without OVA. 
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4.2.6 Discussion 
 
4.2.6.1 Cultured human dendritic cells may not be a suitable model for the assessment of 
the immunogenicity of AGEs 
To assess the immunogenicity of glycated OVA in human cells, cell culture of PBMC-derived 
immature and mature DCs as well as PBMC-derived M1 (pro-inflammatory) and M2 
(anti-inflammatory) macrophages was established. 
The maturation status of the DCs was confirmed by detecting an upregulation of the surface expression 
of CD80, of CD86 and of HLA-DR. Additionally, iDCs express the MR, CD36 and SR-BI, which are 
known to bind to AGEs. Expression of SR-AI/II was not detectable on the cell surface of both iDCs 
and mDCs. This was unexpected, because Jin et al. showed the expression of SR-AI/II on the surface 
of PBMC-derived human iDCs.(113) The used protocol for the isolation and generation of iDCs in 
both studies was very similar, except the cell culture media used for iDC differentiation, i.e. here, a 
serum-free synthetic medium was used, whereas Jin et al. reported the use of RPMI supplemented with 
FCS.(113) Thus, both media were compared, but in our lab no major differences in surface expression 
of SR-AI/II by both types of iDCs could be observed (data not shown). 
By assessing the antigen uptake by human iDCs it was found that AGE-OVA is taken up to a stronger 
extent compared to the native allergen after 240 min incubation time. After 15 min and 60 min 
incubation, no differences in the uptake of AGE-OVA and native OVA could be observed.  
Although AGE-OVA is taken up by iDCs, it can be concluded from these results that human iDCs 
might not be suitable for studying the influence of glycation on the immunogenicity of food allergens 
in human cells, since SR-AI/II, which plays a major role in the murine system, is not expressed by the 
cells. 
 
 
4.2.6.2 Cultured human macrophages may be a suitable model for the assessment of the 
immunogenicity of AGEs 
In contrast to iDCs and mDCs, human macrophages express high levels of SR-AI/II. Other receptors 
binding to AGEs were expressed on the cell surface of M1 and M2 macrophages at different levels. 
M1 macrophages expressed higher levels of the MR and CD36 compared to M2 macrophages. In 
contrast, M2 macrophages expressed SR-AI/II and SR-BI at higher levels than M1 cells. The uptake 
levels of AGE-OVA and native OVA by M1 macrophages were comparable. In contrast, compared to 
native OVA an enhanced antigen uptake of AGE-OVA by M2 macrophages was observed. Several 
studies have shown that M2 macrophages serve as APCs and assist in TH2 responses, like allergic 
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immune responses.(76, 78, 81) Taken together, the results suggest that M2 macrophages are suitable 
model APCs to assess the immunogenicity of AGEs of food allergens in human immune systems. 
Future studies using M2 macrophages and peripheral T-cells derived from food allergic patients will 
further elucidate the T-cell immunogenicity of AGEs of food allergens in allergic individuals. 
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5 Summary 
 
The Maillard reaction takes place between reducing sugars and compounds with free amino groups 
during the thermal processing of foods. In the final stage of the complex reaction cascade, the so-called 
Advanced Glycation Endproducts (AGEs) are formed including proteins with various glycation 
structures. A previous study showed that AGE-modification of ovalbumin (OVA, a major egg white 
allergen) prepared by thermal incubation of OVA with glucose enhances the CD4
+
 T-cell 
immunogenicity of OVA.(71) In this study, we hypothesized that distinct glycation structure(s) 
contribute to the enhanced CD4
+
 T-cell immunogenicity of crude glycated OVA (AGE-OVA). To 
verify this hypothesis, OVA was selectively modified with the glycation structures N
ε
-carboxy-
ethyllysine (CEL), N
ε
-carboxymethyllysine (CML), methylglyoxal-induced hydroimidazolones 
(MG-H1) or pyrraline, which are representative glycation structures found in processed foods. Then, 
the immunogenic and allergenic properties of the modified OVAs were investigated. 
First, the CD4
+
 and the CD8
+
 T-cell immunogenicity of the modified OVAs were assessed using a 
co-culture system of murine bone marrow-derived dendritic cells (BMDCs) with CD4
+
 and 
CD8
+
 T-cells isolated from transgenic mice expressing an OVA-specific T-cell receptor, respectively. 
OVA modified with pyrraline (Pyr-OVA), but not with CEL, CML or MG-H1, possesses a higher 
CD4
+
 T-cell immunogenicity than native OVA. In contrast, the CD8
+
 T-cell immunogenicity of all 
modified OVA samples was similar to that of native OVA. BMDC uptake assay using 
fluorescently-labelled OVA samples showed that Pyr-OVA as well as AGE-OVA, but not the other 
modified OVAs, were highly taken up by BMDCs compared to native OVA. The results suggest that 
the enhanced uptake of Pyr-OVA by BMDCs leads to its enhanced CD4
+
 T-cell immunogenicity. 
Next, the uptake mechanism of Pyr-OVA by BMDCs was investigated using inhibitors of putative 
cell-surface receptors for AGEs as well as BMDCs deficient for these receptors. The macrophage 
scavenger receptor class A (SR-AI/II) and the mannose receptor (MR) mainly mediate the uptake of 
Pyr-OVA and AGE-OVA by BMDCs. The uptake of Pyr-OVA and AGE-OVA was not reduced in 
cells treated with inhibitors of scavenger receptor class B (SR-BI), galectin-3 or blocking antibodies 
against CD36 suggesting that these receptors are not involved in the uptake of Pyr-OVA. In contrast, 
the uptake of Pyr-OVA and AGE-OVA, but not other modified OVAs was remarkably reduced in 
BMDCs deficient for SR-AI/II. Moreover, treatment of SR-A
-/-
 BMDCs with an inhibitor of the MR 
further reduced the uptake of Pyr-OVA and AGE-OVA. The enhanced OVA-specific CD4
+
 T-cell 
activation by Pyr-OVA and AGE-OVA was significantly attenuated in co-culture with SR-A
-/-
 
BMDCs. The results suggest that especially the uptake of Pyr-OVA and AGE-OVA by SR-AI/II leads 
 Summary 95 
to an efficient delivery to the MHC class II loading pathway for antigen presentation and therefore, to 
the enhanced activation of OVA-specific CD4
+
 T-cells. 
Next, the allergenic properties of Pyr-OVA and AGE-OVA were assessed using a mouse model of 
intestinal allergy. BALB/c mice were i.p. sensitized with native OVA, Pyr-OVA or AGE-OVA 
together with ALUM, an adjuvant, twice in a two week interval. Two weeks after the last sensitization, 
mice were fed a diet containing egg white (EW-diet) for one week. After sensitization, enhanced levels 
of OVA-specific IgE antibodies were detected in mice sensitized with Pyr-OVA or AGE-OVA 
compared to native OVA. Feeding of the mice with EW-diet induced stronger clinical symptoms, e.g. 
a more severe loss of body weight and drop in body core temperature, in mice sensitized with 
Pyr-OVA or AGE-OVA compared to native OVA-sensitized mice. The results suggest that Pyr-OVA 
or AGE-OVA could possess a higher allergenic potency than native OVA. IgE antibodies, key 
molecules to induce type I allergic reactions, are produced by B-cells in assistance with TH2-cells, a 
subset of CD4
+
 T-cells. Taken together, Pyr-OVA and AGE-OVA are highly taken up by DCs via 
association with SR-AI/II and this subsequently enhances the CD4
+
 T-cell activation and the IgE 
production. 
In this study, a human cell culture system for assessment of the immunogenicity of glycated allergens 
was also established. We found that human macrophages, but not DCs, are a suitable model. In human 
DCs, SR-AI/II was not expressed on the cell surface. In contrast, human macrophages expressed high 
levels of SR-AI/II and other putative AGE-binding receptors on the cell surface. In particular, M1 
macrophages express higher levels of the MR, whereas M2 macrophages express higher levels of 
SR-AI/II and SR-BI on the cell surface. Additionally, an enhanced uptake of AGE-OVA by M2 
macrophages, but not by M1 macrophages, compared to native OVA was detected. M1 macrophages 
have a pro-inflammatory phenotype and are involved in TH1-type immune responses, whereas M2 
cells have an anti-inflammatory phenotype, but are also regarded as model APCs to assist in TH2-type 
responses. The results indicate that M2 macrophages are an especially suitable model for investigating 
the immunogenicity of glycated food allergens. 
In conclusion, this study demonstrates for the first time that pyrraline is capable of enhancing the 
allergenic properties of a food allergen. High amounts of pyrraline are present in roasted peanuts, a 
clinically relevant allergenic food. The findings suggest that the Maillard reaction could enhance the 
allergenic properties of some food allergens. Moreover, the influence of the Maillard reaction on the 
allergenicity of food allergens needs to be considered in the diagnosis of food allergy, which is usually 
performed using extracts of raw foods or unprocessed purified allergens. Finally, this study would 
contribute to elucidate the molecular mechanisms of food allergies. 
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6 Deutsche Zusammenfassung 
 
Die Allergie ist eine Überempfindlichkeitsreaktion des Immunsystems gegen ansonsten harmlose 
Proteine.(10) Die Prävalenz von Allergien einschließlich der Nahrungsmittelallergien hat in den letzten 
Jahren stark zugenommen.(1) Epidemiologische Studien zeigen, dass ca. 1 % bis 10,8 % der 
Bevölkerung an einer Nahrungsmittelallergie leiden.(1) Die meisten allergischen Reaktionen gegen 
Nahrungsmittel bei Kindern werden von Milch, Hühnereiweiß, Erdnüssen und Schalentieren 
ausgelöst.(1, 2) Bei Erwachsenen jedoch wird selten eine Allergie gegen Milch oder Hühnereiweiß 
nachgewiesen.(3, 4) Neben den Pollen-assoziierten Nahrungsmittelallergien gegen Obst und Gemüse 
leiden erwachsene Patienten häufig an Allergien gegen Schalentiere, Nüsse, Getreide und  
Erdnüsse.(3-5) Die von den Nahrungsmitteln ausgelösten Symptome betreffen den Gastro-
intestinaltrakt, die Haut sowie die Atemwege.(6) Zudem treten in seltenen Fällen schwere systemische 
anaphylaktische Schocks auf, welche lebensbedrohlich sein können.(6) In den meisten Fällen werden 
die Symptome durch eine Immunglobulin E (IgE)-vermittelte Typ-I-Hypersensitivität ausgelöst.(7, 10) 
Dabei wird das Allergen, d. h. das allergieauslösende Protein, von einer antigenpräsentierenden Zelle 
(APC), z. B. einer dendritischen Zelle oder einem Makrophagen, aufgenommen.(7, 10) Nachdem das 
Allergen im Zellinneren prozessiert wurde, werden antigene Peptide auf der Zelloberfläche von 
Molekülen des Haupthistokompatibilitätskomplex (MHC) der Klasse II präsentiert.(7, 10) Diese 
Peptide binden an einen komplementären T-Zellrezeptor (TCR) einer CD4
+
-T-Zelle, welches zur 
Aktivierung und Differenzierung der T-Zelle führt.(7, 10) CD4
+
-T-Zellen können in drei 
unterschiedliche Arten von T-Helferzellen, TH1-, TH2-, TH17-Zellen, oder in regulatorische T-Zellen 
differenzieren.(7, 10) TH2-Zellen werden durch Stimulation von naiven T-Zellen mit den Zytokinen 
Interleukin-4 (IL-4) und IL-13 gebildet und induzieren anschließend die Produktion von 
allergen-spezifischen IgE-Antikörpern durch B-Zellen.(7, 10) Die Antikörper binden an den 
FcεRI-Rezeptor auf der Oberfläche von Mastzellen und ein erneuter Kontakt mit dem Allergen führt zu 
Mastzellaktivierung durch Vernetzung der IgE-Antikörper.(7, 10) Die aktivierten Mastzellen 
sekretieren Histamin und andere physiologisch aktive Mediatoren, welche die allergischen Symptome 
auslösen.(7, 10) Zur Vermeidung von allergischen Symptomen wird den Patienten geraten, das 
entsprechende Nahrungsmittel zu meiden, da nur eine symptomatische und keine heilende Behandlung 
der Nahrungsmittelallergie möglich ist.(2, 6) 
Viele Nahrungsmittel werden nicht roh, sondern in prozessierter Form, d. h. gekocht, gebraten oder 
geröstet, gegessen.(23, 25) Dabei verändern sich die Eigenschaften der Allergene durch chemische 
Reaktionen mit vielen Komponenten in der Matrix.(25, 26) Die häufigste Reaktion zwischen Proteinen 
und Kohlenhydraten während der thermischen Prozessierung von Nahrungsmitteln ist die Maillard 
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Reaktion.(25, 26) Bei der Maillard Reaktion reagieren freie Aminogruppen der Proteine mit der 
Carboxylgruppe eines reduzierenden Zuckers zu einer Vielzahl an Verbindungen, wie z. B. 
N
ε
-Carboxyethyllysin (CEL), N
ε
-Carboxymethyllysin (CML), Pentosidin, Pyrralin oder 
Melanoidinen.(39) Die Gruppe der Maillard-Produkte wird unter dem Begriff „Advanced Glycation 
Endproducts“ (AGEs) zusammengefasst und besteht aus mehreren hundert verschiedenen 
Verbindungen.(39, 40) In einer vorherigen Studie konnte gezeigt werden, dass AGE-modifiziertes 
Ovalbumin (OVA, ein Eiweißallergen), welches durch thermische Inkubation von OVA mit Glucose 
erzeugt wurde, eine erhöhte CD4
+
-T-Zellimmunogenität aufweist im Vergleich zu nativem OVA.(71) 
Daraus wurde folgende Hypothese für diese Arbeit abgeleitet: Die erhöhte CD4
+
-T-Zell-
Immunogenität von AGE-OVA ist auf einzelne Maillard-Verbindungen zurückzuführen. Für die 
Überprüfung dieser Hypothese wurde OVA selektiv mit den Maillard-Verbindungen CEL, CML, 
Pyrralin und Methylglyoxal-induzierten Hydroimidazolonen (MG-H1) modifiziert. Diese Maillard- 
Verbindungen wurden ausgewählt, da sie teils in sehr hohen Mengen in prozessierten Nahrungsmitteln 
nachgewiesen wurden. Anschließend wurden die immunogenen und allergenen Eigenschaften der 
modifizierten OVA-Proben untersucht. 
Zuerst wurden die CD4
+
- und die CD8
+
-T-Zell-Immunogenität der modifizierten OVA-Proben 
bestimmt. Dazu wurden murine dendritische Zellen (DCs) in vitro aus Knochenmarkszellen generiert. 
Außerdem wurden OVA-spezifische T-Zellen aus den Milzen von transgenen Mäusen, welche Zellen 
mit einem OVA-spezifischen T-Zellrezeptor besitzen, isoliert. Die DCs wurden zusammen mit den 
T-Zellen und den modifizierten OVA-Proben inkubiert und die Aktivierung der T-Zellen durch 
Bestimmung der Konzentration des Zytokins IL-2 in den Zellkulturüberständen oder durch Analyse 
der T-Zellproliferation untersucht. Nur für mit Pyrralin modifiziertes OVA (Pyr-OVA) konnte eine 
erhöhte Aktivierung von OVA-spezifischen CD4
+
-T-Zellen und somit eine erhöhte CD4
+
 T-Zell-
Immunogenität nachgewiesen werden. Hingegen wurde die CD8
+
-T-Zellimmunogenität von OVA 
durch keine der Maillard-Verbindungen beeinflusst, da nur eine geringe Aktivierung der 
OVA-spezifischen CD8
+
-T-Zellen für alle Proben, einschließlich unmodifiziertem OVA, beobachtet 
wurde. Diese Ergebnisse legen nahe, dass Pyr-OVA und AGE-OVA im MHC-Klasse-II-Weg der 
dendritischen Zellen effizienter transportiert und prozessiert werden als natives OVA, wohingegen die 
Prozessierung im MHC-Klasse-I-Weg durch die Modifizierung nicht beeinflusst wird. Die effizientere 
Prozessierung und anschließende Antigenpräsentation führt zu der verstärkten Aktivierung von 
OVA-spezifischen CD4
+
-T-Zellen und trägt somit wesentlich zu der CD4
+
-T-Zell-Immunogenität der 
modifizierten OVA-Proben bei. Der Maturierungsstatus der DCs, welcher ebenfalls maßgeblich zu 
einer effizienten T-Zellaktivierung beiträgt, wurde durch die Modifikation von OVA mit 
Maillard-Verbindungen nicht beeinflusst. Ein wichtiger Schritt für eine effiziente Antigenpräsentation 
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und somit auch für die T-Zellaktivierung ist die Aufnahme des Antigens durch die APC. Für die 
Untersuchungen zur Aufnahme der modifizierten OVA-Proben durch DCs wurden die OVA-Proben 
fluoreszenzmarkiert. Die einzelnen OVA-Proben konnten aufgrund eines ähnlichen 
Farbstoff/Protein-Quotienten miteinander verglichen werden. Es wurde gezeigt, dass Pyr-OVA und 
AGE-OVA besser von den DCs aufgenommen wurden im Vergleich zu nativem OVA. Mit CEL, CML 
oder MG-H1 modifiziertes OVA wurde ähnlich gut wie natives OVA von den DCs aufgenommen. 
Aus diesen Ergebnissen wurde gefolgert, dass die verstärkte CD4
+
 T-Zellimmunogenität von Pyr-OVA 
eine Folge der verstärkten Aufnahme von Pyr-OVA durch die DCs ist. 
Im Folgenden wurde der Mechanismus der Aufnahme von Pyr-OVA und AGE-OVA durch die DCs 
untersucht. Mögliche AGE-bindende Rezeptoren, welche auf der Oberfläche von DCs exprimiert 
werden, sind die Scavenger-Rezeptoren Klasse A Typ I und Typ II (SR-AI/II), die 
Scavenger-Rezeptoren der Klasse B, SR-BI und CD36, sowie Galectin-3. Um die Bindung der 
modifizierten OVA-Proben an diese Rezeptoren zu untersuchen wurden entweder spezifische 
Inhibitoren oder Rezeptor-defiziente DCs verwendet. Die Verwendung von SR-AI/II-defizienten 
Zellen ergab eine reduzierte Aufnahme von Pyr-OVA und AGE-OVA, wohingegen bei Inhibition der 
Rezeptoren SR-BI, CD36 und Galectin-3 eine vergleichbare Aufnahme zu unbehandelten Zellen 
beobachtet wurde. Weiterhin wurde gezeigt, dass der Mannose-Rezeptor (MR) ebenfalls zu der 
verstärkten Aufnahme von Pyr-OVA und AGE-OVA beiträgt, da er nicht nur die intrinsische 
Glykosylierung von OVA erkennt sondern auch AGEs bindet. Jedoch scheint die MR-vermittelte 
Aufnahme der AGEs eine untergeordnete Rolle für die CD4
+
-T-Zellimmunogenität von Pyr-OVA und 
AGE-OVA zu spielen, da die Verwendung von SR-AI/II-defizienten DCs in der Ko-Kultur mit 
OVA-spezifischen CD4
+
 T-Zellen im Vergleich zu Wildtyp-DCs zu einer deutlich reduzierten 
CD4
+
-T-Zellaktivierung durch Pyr-OVA und AGE-OVA führte. Aus diesem Ergebnis lässt sich 
folgern, dass die verstärkte CD4
+
-T-Zellimmunogenität hauptsächlich durch die starke SR-AI/II-
vermittelte Aufnahme von Pyr-OVA und AGE-OVA durch DCs, welche zu einem effizienteren 
Transport in den MHC-Klasse-II-Weg führt, ausgelöst wird. 
Anschließend wurden die allergenen Eigenschaften von Pyr-OVA und AGE-OVA in einem 
Mausmodell der intestinalen Allergie untersucht. BALB/c-Mäuse wurden intraperitoneal mit nativem 
OVA, Pyr-OVA oder AGE-OVA in Kombination mit dem Adjuvans Aluminiumhydroxid zweimal in 
einem zweiwöchigen Intervall sensibilisiert. Zwei Wochen nach der letzten Sensibilisierung wurden 
die Mäuse für eine Woche mit einem Futter, welches hohe Mengen an Hühnereiweiß enthielt, 
gefüttert. Die Sensibilisierung der Mäuse mit Pyr-OVA oder AGE-OVA induzierte eine stärkere 
Produktion an OVA-spezifischen IgE im Vergleich zu der Sensibilisierung mit nativem OVA. 
Zusätzlich zeigten die Pyr-OVA- und AGE-OVA-sensibilisierten Mäuse stärkere klinische Symptome, 
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d. h. einen höheren Gewichtsverlust sowie Senkung der Körpertemperatur, während der Fütterung mit 
Hühnereiweiß-haltigem Futter als Mäuse, welche mit nativem OVA sensibilisiert wurden. Diese 
Ergebnisse deuten daraufhin, dass die allergene Wirkung von OVA durch die Modifizierung mit 
Pyrralin oder AGEs verstärkt wird. Der Zusammenhang zwischen der erhöhten 
CD4
+
-T-Zellimmunogenität von Pyr-OVA und AGE-OVA und der erhöhten allergenen Wirkung 
ergibt sich daraus, dass die Stärke der IgE-Produktion durch B-Zellen über den Grad der Aktivierung 
der CD4
+
-T-Zellen geregelt wird. 
Im letzten Teil dieser Arbeit wurde eine Zellkultur-Methode mit primären humanen Zellen für die 
Analyse der Immunogenität von Maillard-modifizierten Allergenen etabliert. Es zeigte sich, dass 
humane dendritische Zellen nicht für diesen Zweck geeignet sind, da sie den SR-AI/II nicht auf der 
Zelloberfläche exprimieren. Humane Makrophagen hingegen weisen eine starke Oberflächen-
expression von SR-AI/II und anderen AGE-bindenden Rezeptoren auf. Der MR ist verstärkt auf der 
Oberfläche von M1-Makrophagen zu finden, wohingegen M2-Zellen mehr Kopien der Rezeptoren 
SR-AI/II und SR-BI auf der Zelloberfläche tragen. Desweiteren konnte gezeigt werden, dass 
M2-Makrophagen, jedoch nicht M1-Zellen, AGE-OVA besser aufnehmen als natives OVA. 
M1-Makrophagen haben einen pro-inflammatorischen Phänotyp und wirken bei Immunreaktionen des 
TH1-Typs mit. M2-Makrophagen besitzen einen anti-inflammatorischen Phänotyp und fungieren als 
APCs in Immunantworten des TH2-Typs. Zusammenfassend lässt sich sagen, dass M2-Makrophagen 
ein sehr gutes Modellsystem für die Analyse der Immunogenität von Maillard-modifizierten Proteinen 
darstellen. 
 
Diese Arbeit zeigt erstmalig, dass die Modifizierung eines Nahrungsmittelallergens mit Pyrralin, 
einem Produkt der Maillard-Reaktion, zu einer Verstärkung der allergenen Wirkung führt. Große 
Mengen an Pyrralin wurden in gerösteten Erdnüssen, welche häufig sehr starke klinische Symptome 
auslösen, nachgewiesen. Diese Resultate deuten daraufhin, dass die Maillard-Reaktion eine 
verstärkende Wirkung auf die allergenen Eigenschaften einiger Nahrungsmittelallergene hat. 
Deswegen sollte der Einfluss der Maillard-Reaktion auf die Allergenität von Nahrungsmittelallergenen 
in der Allergiediagnostik berücksichtigt werden, welche normalerweise mit Extrakten aus rohen 
Nahrungsmitteln oder unprozessierten aufgereinigten Allergenen durchgeführt wird. Abschließend 
lässt sich sagen, dass diese Arbeit zu der Aufklärung der molekularen Mechanismen der 
Nahrungsmittelallergie beiträgt. 
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